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PSTATE-OF-THE-ART PAPERS
Coronary Stents
Current Status
Scot Garg, MB, CHB, Patrick W. Serruys, MD, PHD
Rotterdam, the Netherlands
Coronary artery stents revolutionized the practice of interventional cardiology after they were first introduced in
the mid-1980s. Since then, there have been significant developments in their design, the most notable of which
has been the introduction of drug-eluting stents. This paper reviews the benefits, risks, and current status of
Food and Drug Administration-approved drug-eluting stents. (J Am Coll Cardiol 2010;56:S1–42) © 2010 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.06.007T
a
T
h
v
t
c
i
k
p
A
d
t
s
b
w
i
p
w
h
c
a
n
(
(
c
t
(
P
t
n
w
en 1964, Charles Theodore Dotter and Melvin P. Judkins
escribed the first angioplasty (1). Thirteen years later,
ndreas Grüntzig performed the first balloon coronary
ngioplasty (2), a revolutionary treatment that lead to the
irth of a new specialty, interventional cardiology. Since
hat first procedure, there have been extensive developments
nd advances that have culminated in percutaneous coronary
ntervention (PCI) being 1 of the most frequently per-
ormed invasive medical procedures in clinical practice
oday.
Coronary stents, which were first developed in the mid-
980s (3), have ultimately replaced “plain old balloon
ngioplasty” (POBA) as the preferred method of perform-
ng PCI, after the observed improvements in angiographic
nd clinical outcomes seen with their use (4,5). The major-
ty of PCI procedures now involve a coronary stent, and
herefore, interventional cardiologists are faced with a wide
hoice of coronary stents to implant. This choice ranges
rom conventional bare-metal stents (BMS) and drug-
luting stents (DES) that are widely used in contemporary
ractice to newer stents such as DES with biodegradable
olymers, DES that are polymer-free, DES with novel
oatings, dedicated bifurcation stents, self-expanding stents,
nd biodegradable stents.
Part 1 of this review discusses the current status of
oronary stents and examines some of the unresolved issues
urrounding their implantation in contemporary practice.
art 2 will review the vast array of new coronary stents that
re currently undergoing evaluation in pre-clinical and
linical trials.
rom the Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical
enter, Rotterdam, the Netherlands. Drs. Garg and Serruys report that they have no
elationships to disclose.(
Manuscript received December 9, 2009; revised manuscript received June 1, 2010,
ccepted June 15, 2010.he Need for Coronary Stents
nd the Early Period
here is no dispute that POBA was a pioneering treatment;
owever, its success was hindered by the problems of acute
essel closure and restenosis (4–6). These problems lead to
he development of a second revolutionary treatment, the
oronary stent, which was first implanted by Sigwart et al. (3)
n 1986 (Fig. 1) (7). This bare metal, self-expanding stent,
nown as the “Wall” stent was able to provide a scaffold that
revented acute vessel closure and late constrictive recoil (3).
lthough these initial stents proved effective as “bailout”
evices in cases of abrupt or threatened vessel closure,
hereby reducing rates of emergency coronary artery bypass
urgery (CABG) (8), development was ultimately hampered
y the risk of subacute thrombotic coronary artery occlusion,
hich was observed in up to 18% of cases within 2 weeks of
mplantation (9). This novel, stent-specific hazard
rompted the use of complex anticoagulation regimens that
ere associated with increased bleeding and prolonged
ospitalization (10). Overall, the early success and compli-
ation rates seen with these initial coronary stents were not
lways competitive with those of routine POBA.
Coronary stenting only became a widely accepted tech-
ique after the publication of the landmark BENESTENT
Belgian Netherlands Stent) trial (11) and the STRESS
Stent Restenosis Study) (12), together with evidence indi-
ating that stenting was safe in the absence of anticoagula-
ion therapy with the use of dual antiplatelet therapy
DAPT) (13–15) and/or adequate stent deployment (16).
By 1999, coronary stenting was performed in 84.2% of
CI procedures (17); however, despite their obvious advan-
ages, there were associated problems and concerns. Most
otably, and in addition to the risk of subacute thrombosis,
hich has already been alluded to, an iatrogenic problem
merged in the form of in-stent neointimal hyperplasia
18–20). This intrastent growth of scar tissue, which was
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migration of vascular smooth
muscle cells, and as demon-
strated in Figure 2 was directly
linked to stent implantation, re-
sulted in restenosis rates of 20%
to 30% (21). It was the attempts
to minimize this in-stent neoin-
timal hyperplasia, and thereby
reduce rates of repeat revascular-
ization, that ultimately lead to
the development of another rev-
olutionary treatment: the DES.
The dramatic reduction in reste-
nosis rates seen with the use of
these DES compared with BMS
(22–26) has been the major driv-
ing force behind the exponential
growth of PCI as a treatment for
patients with coronary artery dis-
ease (CAD). After the outstand-
ing results from the early pivotal
trials with DES, there was an
increased confidence to use PCI,
so that its use has expanded to
lesions subsets that were only
previously considered suitable for
CABG (27–29). This increased
confidence lead to a rapid and
unprecedented uptake in their
use, so that by 2005, 80% to 90%
of all revascularization proce-
dures in the U.S. were performed
using a DES (30). In 2006, con-
cerns were raised over the safety
profile of these stents (31–33),
resulting in an immediate world-
wide downturn in their use.
These concerns proved a vital
stimulus to focus research, and
have ultimately lead to the devel-
opment of newer stents and im-
proved safety, resulting in a re-
surgence in the use of DES;
however, current rates (75%)
are still below those of 2005 (34).
DES Initial Phase:
“The Rosy Period”
Sirolimus-eluting stents (SES).
In the late 1990s, numerous pre-
clinical studies reported that siroli-
mus (previously called rapamycin),
macrolide antibiotic that was approved for use as an immu-
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
BMS  bare-metal stent(s)
CABG  coronary artery
bypass grafting
CAD  coronary artery
disease
CI  confidence interval
CoCr  cobalt chromium
CTO  chronic total
occlusion
DAPT  dual antiplatelet
therapy
DES  drug-eluting stent(s)
EES  everolimus-eluting
stent(s)
FDA  Food and Drug
Administration
HR  hazard ratio
ISA  incomplete stent
apposition
ISR  in-stent restenosis
IVUS  intravascular
ultrasound
MACE  major adverse
cardiovascular events
MI  myocardial infarction
MVD  multivessel disease
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
POBA  plain old balloon
angioplasty
RR  relative risk
SES  sirolimus-eluting
stent(s)
ST  stent thrombosis
STEMI  ST-segment
elevation myocardial
infarction
SVG  saphenous vein
graft
TLR  target lesion
revascularization
TVR  target vessel
revascularization
UPLMS  unprotected left
main stem
ZES  zotarolimus-eluting
stent(s)osuppressant to prevent organ rejection, was able to inhibit (he cytokine- and growth-factor–mediated proliferation of
ymphocytes and smooth muscle cells, resulting in reduced
eointimal proliferation (Fig. 3) (35–38). Despite its promise,
roblems remained over the ability to locally deliver sirolimus
t an appropriate and sustained concentration necessary to
nhibit neointimal proliferation. Failures with both oral admin-
stration and local delivery using special delivery balloons led to
he development of a coronary stent with a drug coating, the
ES. The first human DES implant was performed by J.
duardo Sousa in Sao Paulo in December 1999 at the start of
he 2 first-in-man studies that recruited a total of 45 patients
nd reported minimal in-stent neointimal proliferation
hrough to 12-month follow-up (39–41). This research cul-
inated in the development and commercial launch of the
tainless steel Cypher SES (Cordis, Warren, New Jersey), the
pecification of which is summarized in Table 1. The Cypher
ES was initially evaluated in the pivotal RAVEL (Random-
zed Study With the Sirolimus-Coated Bx Velocity Balloon-
xpandable Stent in the Treatment of PatientsWith De Novo
ative Coronary Artery Lesions) study, which randomly as-
igned 238 patients with relatively low risk lesions to treatment
ith the Cypher SES or BMS controls. At 1-year follow-up,
he rate of binary stenosis was 0.0% and 26.6% for patients
reated with Cypher SES and BMS, respectively (42). These
esults were subsequently confirmed in the much larger
IRIUS (Sirolimus-Eluting Stent in De-Novo Native Coro-
ary Lesions) trial that enrolled 1,058 patients with more
omplex lesions than were seen in the RAVEL study. This
tudy again demonstrated significantly lower rates of target
esion revascularization (TLR) and major adverse cardiovascu-
ar events (MACE) after treatment with the Cypher SES
ompared with BMS controls at 9-month, 2-year, and now
-year follow-up (43–45).
After these initial randomized studies, which ultimately
ead to regulatory approval, the performance of the Cypher
tent has been assessed in: 1) different patient types, for
xample, diabetic patients; 2) different clinical settings,
ncluding primary PCI for ST-segment elevation myocar-
ial infarction (STEMI); and 3) different lesion types
ncluding chronic total occlusions (CTO), saphenous vein
rafts (SVG), small coronary vessels, and complex lesions.
he results of the most important randomized controlled
rials comparing SES and BMS in these different clinical
ettings are summarized in Table 2 (42–75). As clearly
emonstrated, when compared with BMS, the use of SES
esults in significant reductions in angiographic in-stent late
oss, in-stent angiographic (binary) restenosis, and repeat
evascularization at both short- and long-term follow-up,
ith results consistent across numerous different patient and
esion types. Furthermore, meta-analyses of patient data
rom the initial approval trials reaffirms the sustained
dvantage of SES over BMS in terms of reduced repeat
evascularization, together with comparable rates of death
nd myocardial infarction (MI) at long-term follow-up
Table 3) (22–26,76).
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August 31, 2010:S1–42 Coronary Stents: Current StatusIn addition to randomized data, registries have evaluated
he performance of the Cypher stent in the setting of the
eal-world. The first of these registries was the single-center
ESEARCH (Rapamycin-Eluting Stent Evaluated at Rot-
erdam Cardiology Hospital) registry, which enrolled 508
onsecutive patients who were treated with the Cypher SES
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Figure 1 First Human Coronary Stent Implantation, March 198
(A) A restenotic lesion after balloon angioplasty. (B) The self-expanding WALLSTEN
(D) Angiographic results at 11-year follow-up. Reproduced with permission from CaFigure 2 Pathway Leading to In-Stent Restenosis After Stent Implanrrespective of lesion complexity. Running concurrently with
he RESEARCH registry was the multicenter ARTS-II
Arterial Revascularization Therapies Study) registry, which
ssessed the Cypher stent in 607 patients with 2- and
-vessel CAD. Results from both registries at short- and
ong-term follow-up, which now extends to 4 and 5 years,
stenosis post balloon angioplasty
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Coronary Stents: Current Status August 31, 2010:S1–42espectively, for the RESEARCH and ARTS-II registries
Fig. 4) (77), mirrors those from other registries and the
reviously noted randomized studies and meta-analyses, by
Figure 3 Sirolimus
(A) The chemical structure of the macrocylic lactone group of antiproliferative
drugs. (B) The mode of action of sirolimus: sirolimus binds to the FK-binding
protein 12 (FKBP12), which in turn inhibits the mammalian target of rapamycin
(mTOR) pathway. This subsequently prevents the downregulation of the cell
division kinase inhibitor p27kip1, thereby inhibiting cell division between phases
G1 and S1 of the cell cycle. Sirolimus has a wide dose range, is cytostatic as
opposed to cytotoxic, and has additional anti-inflammatory properties through
its inhibition of interleukin-2, which reduces T- and B-cell activation. DNA 
deoxyribonucleic acid.ontinuing to demonstrate significantly lower rates of Sp
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Summary of Major Randomized Trials of SES Versus BMS in Different Clinical SettingsTable 2 Summary of Major Randomized Trials of SES Versus BMS in Different Clinical Settings
Trial or First Author
(Ref. #) No. of Patients Clinical Setting
Follow-Up,
Months
In-Stent
Late Loss
(SES vs.), mm
Binary In-Stent
Restenosis
(SES vs.), %
MACE
(SES vs.), %
Death
(SES vs.), %
MI
(SES vs.), %
TLR
(SES vs.), %
Definite/
Probable ST
(SES vs.), %
RAVEL (42,46) SES (n  120) vs. BMS (n  118) Elective simple lesions 6*/12† 0.01 vs. 0.80‡ 0.0 vs. 26.6‡ 5.8 vs. 28.8‡ 1.7 vs. 1.7 3.3 vs. 4.2 0.0 vs. 23.7§ 0.0 vs. 1.7
60 NA NA 25.8 vs. 35.2§ 12.1 vs. 7.1 8.9 vs. 6.9 10.3 vs. 26.0‡ 1.7 vs. 2.5
C-SIRIUS (47) SES (n  50) vs. BMS (n  50) Canadian approval
trial
8*/9† 0.12 vs. 1.02‡ 0.0 vs. 45.5‡ 4.0 vs. 18.0 0.0 vs. 0.0 2.0 vs. 4.0 4.0 vs. 18.0 2.0 vs. 2.0
E-SIRIUS (48) SES (n  175) vs. BMS (n  177) Elective long lesions,
small vessels,
overlapped stents
8*/9† 0.20 vs. 1.05‡ 3.9 vs. 41.7‡ 8.0 vs. 22.6‡ 1.1 vs. 0.6 4.6 vs. 2.3 4.0 vs. 20.9‡ 1.1 vs. 0.0
SIRIUS (43,45) SES (n  163) vs. BMS (n  159) U.S. pivotal approval
trial
8*/12† 0.17 vs. 1.00‡ 3.2 vs. 35.4‡ 8.3 vs. 23.2‡ 1.3 vs. 0.8 3.0 vs. 4.2 4.9 vs. 20.2‡ 0.4 vs. 1.1
60 NA NA 20.3 vs. 33.5‡ 8.4 vs. 8.4 6.2 vs. 6.5 9.4 vs. 24.2‡ 1.2 vs. 1.8
DIABETES (49,51) SES (n  80) vs. BMS (n  80) Diabetes 9*/24† 0.09 vs. 0.67‡ 3.9 vs. 31.7‡ 12.8 vs. 41.3‡¶ 2.6 vs. 3.8¶ 3.8 vs. 8.8 7.7 vs. 35.0‡ 3.8 vs. 2.5#
48 NA NA NA 4.1 vs. 6.5¶ 4.1 vs. 10.4 8.1 vs. 37.7‡ 3.8 vs. 3.8#
DESSERT (52) SES (n  75) vs. BMS (n  75) Diabetes 8*/12† 0.14 vs. 0.96‡ 3.6 vs. 38.8‡ 22.1 vs. 44.0§ 4.4 vs. 2.9 16.2 vs. 20.0 5.9 vs. 30.0‡ 1.4 vs. 1.5
SCORPIUS (53) SES (n  98) vs. BMS (n  102) Diabetes 8*/12† 0.22 vs. 0.99‡ 8.8 vs. 42.1‡ NA 5.3 vs. 4.1 4.3 vs. 5.2 5.3 vs. 21.1‡ 2.1 vs. 2.1
Diaz de la Llera et al. (54) SES (n  60) vs. BMS (n  60) STEMI 12 NA NA 6.7 vs. 11.1 5.0 vs. 3.6 6.7 vs. 5.4
(DeathMI)
0.0 vs. 5.7** 3.4 vs. 1.8#
MISSION! (55,56) SES (n  158) vs. BMS (n  152) STEMI 9*/12† 0.19 vs. 0.95‡ 2.3 vs. 22.6‡ NA 1.3 vs. 2.6 5.7 vs. 9.2 3.2 vs. 11.2§ 1.3 vs. 2.0
36 NA NA NA 4.4 vs. 6.6 7.6 vs. 11.2 6.3 vs. 12.5 3.1 vs. 2.0
PASEO (57,58) SES (n  90) vs. BMS (n  90) STEMI 12 NA NA 11.1 vs. 24.4§ 3.3 vs. 6.7 4.4 vs. 6.7 3.3 vs. 14.4§ 0.0 vs. 1.1††
48 NA NA 36.7 vs. 21.1§ 7.8 vs. 12.2 8.9 vs. 13.3 5.6 vs. 21.1§ 1.1 vs. 2.2††
SESAMI (59,60) SES (n  160) vs. BMS (n  160) STEMI 12 0.18 vs. 0.85§ 9.3 vs. 21.3§ 6.8 vs. 16.8§ 1.8 vs. 4.3 1.8 vs. 1.8 4.3 vs. 11.2§ 1.2 vs. 0.6††
36 NA NA 12.7 vs. 21.0§ 3.2 vs. 5.0 2.5 vs. 2.5 7.0 vs. 13.5§ 1.9 vs. 1.3††
STRATEGY (61,62) SES (n  87) vs. BMS (n  88) STEMI 8 0.22 vs. 0.60‡ 7.5 vs. 28§ 18.4 vs. 31.8§ 8.0 vs. 9.1 6.9 vs. 9.1 5.7 vs. 20.5§ 0.0 vs. 2.3#
60 NA NA 29.9 vs. 43.2 18.0 vs. 16.0 22.0 vs. 25.0
(DeathMI)
10.3 vs. 26.1§** 7.0 vs. 8.0‡‡
TYPHOON (63,64) SES (n  355) vs. BMS (n  357) STEMI 8*/12† 0.14 vs. 0.83‡ 3.5 vs. 20.3§ 5.9 vs. 14.6‡ 2.3 vs. 2.2 1.1 vs. 1.4 5.6 vs. 13.4‡ 2.4 vs. 3.6
48 NA NA NA 4.0 vs. 6.4 4.8 vs. 4.0 7.2 vs. 15.2§ 4.4 vs. 4.8
Pache et al. (65) SES (n  250) vs. BMS (n  250) Elective all-comers 6*/12† 0.14 vs. 0.94‡ 8.3 vs. 25.5‡ 13.6 vs. 22.4§** 2.8 vs. 2.0 4.6 vs. 2.8 7.2 vs. 18.8‡** 0.8 vs. 0.4
PRISON II (66,68) SES (n  100) vs. BMS (n  100) Chronic total occlusion 6*/12† 0.05 vs. 1.09‡ 7.0 vs. 36.0‡ 5.0 vs. 24.0‡ 0.0 vs. 1.0 2.0 vs. 3.0 5.0 vs. 21.0§ 2.0 vs. 0.0‡‡
60 NA NA 12.0 vs. 36.0‡ 5.0 vs. 5.0 8.0 vs. 7.0 12.0 vs. 30.0§ 8.0 vs. 3.0‡‡
GISSOC II-GISE (69) SES (n  78) vs. BMS (n  74) Chronic total occlusion 8*/24† 0.20 vs. 1.57‡ 8.2 vs. 67.7‡ 17.6 vs. 50.0‡ 2.7 vs. 1.3 2.7 vs. 5.1 8.1 vs. 44.9‡ 1.4 vs. 1.3
SES-SMART (70,71) SES (n  129) vs. BMS (n  128) Small vessels 8 0.16 vs. 0.90‡ 4.9 vs. 49.1‡ 9.3 vs. 31.3‡§§ 0.0 vs. 1.6 1.6 vs. 7.8§ 7.0 vs. 21.1§ 0.8 vs. 3.1#
24 NA NA 12.6 vs. 33.1‡§§ 0.8 vs. 3.9 1.6 vs. 10.2§ 7.9 vs. 29.9‡ 0.8 vs. 3.1#
SCANDSTENT (72,73) SES (n  163) vs. BMS (n  159) Complex disease 6*/7† 0.02 vs. 1.01‡ 2.0 vs. 30.6‡ 4.3 vs. 29.9‡ 0.6 vs. 0.6 1.2 vs. 3.1 2.5 vs. 29.3‡ 0.6 vs. 3.8
36 NA NA 12.3 vs. 37.6‡ 5.6 vs. 1.9 3.7 vs. 9.6 4.9 vs. 33.8‡ 1.2 vs. 4.4
RRISC (74,75) SES (n  38) vs. BMS (n  37) Saphenous vein grafts 6 0.38 vs. 0.79§ 11.3 vs. 30.6§ 15.8 vs. 29.7 2.6 vs. 0.0 2.6 vs. 0.0 5.3 vs. 21.6§ 0.0 vs. 0.0
32 NA NA 57.9 vs. 40.5 28.9 vs. 0.0‡ 18.4 vs. 5.4 23.7 vs. 29.7 5.0 vs. 0.0††
Differences are nonsignificant unless indicated. Stent thrombosis defined per Academic Research Consortium definitions, unless indicated. All trial acronyms are listed in the Online Appendix. *Angiographic follow-up. †Clinical follow-up. ‡p  0.001. §p  0.05. Ischemia
driven. ¶Cardiac. #Protocol-defined ST. **Target vessel revascularization. ††Definite ST only. ‡‡Definite, probable, and possible. §§Major adverse cardiovascular and cerebrovascular events.
BMS  bare-metal stent(s); MACE  major adverse cardiovascular events (a composite of death, myocardial infarction, and target lesion revascularization); MI  myocardial infarction; NA  not available; SES  sirolimus-eluting stent(s); ST  stent thrombosis;
STEMI  ST-segment elevation myocardial infarction; TLR  target lesion revascularization. S5
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Coronary Stents: Current Status August 31, 2010:S1–42ACE and TLR after the use of the Cypher SES com-
ared with historical BMS controls (77–81).
aclitaxel-eluting stents (PES). The TAXUS PES (Bos-
on Scientific, Natick, Massachusetts) was developed almost
imultaneously with the SES, gaining regulatory approval12
onths later (Table 1, Fig. 5). Its evaluation has followed a
ates of Death, MI, and TLR From Recent Meta-Analyses of DES CTable 3 Rates of Death, MI, and TLR From Recent Meta-Analys
First Author (Ref. #) Number of Patients Longest Fol
SES vs. BMS
Stettler et al. (22) 8,646 (4,643 SES, 4,003 BMS) 4
Stone et al. (24) 1,748 (878 SES, 870 BMS) 4
Kastrati et al. (26) 4,958 (2,486 SES, 2,472 BMS) 5
PES vs. BMS
Stettler et al. (22) 8,330 (4,327 PES, 4,003 BMS) 4
Stone et al. (24) 3,513 (1,755 PES, 1,758 BMS) 4
Other
Stettler et al. (22) 8,970 (4,643 SES, 4,327 PES) 4
Kirtane et al. (76), on-label
Kirtane et al. (76), off-label 9,470 (4,867 DES, 4,603 BMS) 5
ifferences nonsignificant unless indicated. *p  0.05. †p  0.001. ‡Combined death or MI. §Co
DES  drug-eluting stent(s); HR  hazard ratio; PES  paclitaxel-eluting stent(s); TVR  target
Figure 4 Long-Term Clinical Outcomes of SES, BMS, and CABG
Long-term clinical outcomes compared for patients treated with sirolimus-eluting s
bypass graft surgery (CABG [black lines]) in the ARTS (Arterial Revascularization T
(B) death, cerebrovascular accident (CVA), and myocardial infarction (MI), (C) repe
events (MACCE). Reproduced with permission from Serruys et al. (77).attern similar to that of the SES, and its first assessment, in
he randomized TAXUS I study, reported no binary restenosis
t 6-month follow-up (82). Subsequent randomized studies,
he most important of which are summarized in Table 4, have
emonstrated a significantly lower rate of late loss, angio-
raphic binary restenosis, and repeat revascularization with
red to BMSf DES Compared to BMS
, yrs Death (DES vs. BMS) MI (DES vs. BMS) TLR (DES vs. BMS)
HR: 1.0 HR: 0.81* HR: 0.3†
6.7% vs. 5.3% 6.4% vs. 6.2% 7.8% vs. 23.6%†
6.0% vs. 5.9% 9.7% vs. 10.2%‡ HR: 0.43§†
HR: 1.03 HR: 1.0 HR: 0.42†
6.1% vs. 6.6% 7.0% vs. 6.3% 10.1% vs. 20.0%†
HR: 0.96 HR: 0.83* HR: 0.70*
HR: 1.05 HR: 1.03 HR: 0.54†
HR: 0.84 HR: 0.83 HR: 0.42†
death, MI, or TVR.
revascularization; other abbreviations as in Table 2.
RTS I and II
SES [red lines]), bare-metal stents (BMS [blue lines]), and coronary artery
Studies) I and II (77). Kaplan-Meier estimates for freedom from (A) death,
ascularization, and (D) overall major adverse cardiovascular and cerebrovascularompaes o
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August 31, 2010:S1–42 Coronary Stents: Current StatusES compared with BMS that is consistent across different
atient groups including those with simple lesions, STEMI,
esions in the unprotected left main stem (UPLMS), and
omplex lesions (57,82–96). In addition, patient-level meta-
nalysis of the initial PES approval trials has confirmed the
omparable safety and superior efficacy of PES compared with
MS out to 4-year follow-up (Table 3) (22,24).
In a fashion similar to the SES, the TAXUS PES stent
as been assessed in an unrestricted single-center registry
hat used the PES as the default stent for all PCI in 576
onsecutive real-world patients. Two-year results from the
-SEARCH (Taxus Stent Evaluated at Rotterdam Cardi-
logy Hospital) registry demonstrate similar efficacy in
erms of suppression of neointimal growth and reduction of
estenosis when compared with historical controls treated
ith SES (97,98).
AXUS EXPRESS VERSUS TAXUS LIBERTÉ. The first PES to
e approved by the Food and Drug Administration (FDA)
as the TAXUS PES Express stent. This was subsequently
Figure 5 Paclitaxel
(A) The chemical structure and (B) mode of action of paclitaxel, an extract
derived from the bark of the Taxus brevifolia (Pacific Yew) tree. Paclitaxel inhib-
its smooth muscle cell proliferation through the stabilization of microtubules,
and thereby inhibits cell division.uperseded by the TAXUS PES Liberté stent, which was resigned to be more deliverable and conformable and to
rovide a more homogenous drug distribution (99). Table 1
ummarizes the main physical properties of both stents,
oth of which have the same polymer and dose of paclitaxel;
owever, the Liberté stent has a more uniform cell geometry
Fig. 6) (99), allowing more enhanced and uniform drug
elivery, thinner struts (97 m vs. 132 m), a smaller
rofile, and separate stent designs depending on stent
iameter. Stents with a diameter of 2.25 to 2.5 mm have a
-cell design, whereas stents with a diameter 2.75 mm
ave a 3-cell design. The superiority of the Liberté stent was
onfirmed through the multicenter noninferiority TAXUS
TLAS (TAXUS Liberté-SR Stent for the Treatment of
e Novo Coronary Artery Lesion) clinical trial, which
nrolled 871 patients treated with the TAXUS Liberté stent
ho were compared with a historical population of patients
reated with the TAXUS Express-SR stent from the
AXUS IV and V trials (99). In spite of similar inclusion
riteria, patients receiving the Liberté stent had treatment
or significantly more complex baseline lesions. Neverthe-
ess, the primary end point of 9-month target vessel revas-
ularization (TVR) occurred in 7.0% and 8.0% of patients
reated with the Express and Liberté stents, respectively,
chieving the pre-specified criteria for noninferiority (p 
.049). There were no significant differences in other
linical outcomes.
Two additional multicenter studies confirmed the im-
roved outcomes with the newer Liberté stent. These were
he TAXUS ATLAS Small Vessels study and the TAXUS
TLAS Long Lesions study.
The TAXUS ATLAS Small Vessels study, which com-
ared the performance of the 2.25-mm TAXUS Liberté
tent in 261 patients with 75 historical controls from the
AXUS V study who had had a lesion treated with a single
.25-mm TAXUS Express stent (100). In addition to
eeting the noninferiority primary end point of 9-month
n-segment diameter stenosis, compared with the Express
tent, the Liberté stent was shown to significantly reduce
he rate of 9-month angiographic restenosis (18.5% vs.
2.7%, p  0.02) and TLR at 12 months (6.1% vs. 16.9%,
 0.004). Moreover, at 3-year follow-up, the use of the
AXUS Liberté led to a significant reduction in TLR
10.0% vs. 22.1%, p  0.008) and MACE (19.5% vs.
2.4%, p  0.03), together with a numerically lower
omposite of death/stroke and MI (6.5% vs. 7.4%, p 
.79) (101).
The TAXUS ATLAS Long Lesions study compared the
erformance of the 38-mm long TAXUS Liberté stent in
50 patients with lesions between 26 mm and 34 mm in
ength with that of 145 historical control patients from the
AXUS IV and V studies with similar length lesions treated
ith a least 1 Express stent (100). In addition to meeting
he noninferiority primary end point of 9-month in-
egment diameter stenosis, compared with the Express
tent, the Liberté stent was also shown to significantly
educe the risk of MI at both 12-month follow-up (1.4% vs.
Summary of Major Randomized Trials of PES Versus BMS in Different Clinical SettingsTable 4 Summary of Major Randomized Trials of PES Versus BMS in Different Clinical Settings
Trial or First Author
(Ref. #) No. of Patients Clinical Setting
Follow-Up,
Months
In-Stent
Late Loss
(PES vs.), mm
Binary In-Stent
Restenosis
(PES vs.), %
MACE
(PES vs.), %
Death
(PES vs.), %
MI
(PES vs.), %
TLR
(PES vs.), %
Definite/Probable ST
(PES vs.), %
TAXUS-I (82) PES (n  31) vs.
BMS (n  30)
Simple lesions 6*/12† 0.36 vs. 0.71 0.0 vs. 10.4 3.3 vs. 10.0‡ 0.0 vs. 0.0 0.0 vs. 0.0 (Q-wave only) 0.0 vs. 10.0§ 0.0 vs. 0.0
TAXUS-II Slow
release (83,84)
PES (n  131) vs.
BMS (n  136)
Simple lesions 6*/12† 0.31 vs. 0.79 2.3 vs. 17.9 10.9 vs. 22.0¶# 0.0 vs. 1.5 2.4 vs. 5.3 4.7 vs. 12.9¶ 0.7 vs. 0.0**
60 NA NA 20.4 vs. 27.6‡†† 2.4 vs. 1.5†† 4.7 vs. 7.1 10.3 vs. 18.4¶ 2.7 vs. 0.8**
TAXUS-II Moderate
release (83,84)
PES (n  135) vs.
BMS (n  134)
Simple lesions 6*/12† 0.30 vs. 0.77 4.7 vs. 20.2 9.9 vs. 21.4¶# 0.0 vs. 0.0 3.8 vs. 5.4 3.8 vs. 16.0¶ 0.7 vs. 0.0**
60 NA NA 15.1 vs. 27.6‡¶†† 1.6 vs. 1.5†† 5.3 vs. 7.1 4.5 vs. 18.4 1.7 vs. 0.8**
TAXUS-IV (85,86) PES (n  662) vs.
BMS (n  652)
Pivotal approval
trial
9 0.39 vs. 0.92 5.5 vs. 24.4 8.5 vs. 15.0††‡‡ 2.4 vs. 2.2 3.5 vs. 3.7 3.0 vs. 11.3‡‡ 0.8 vs. 1.1
60 NA NA 24.0 vs. 32.0‡†† 10.0 vs. 11.2 7.2 vs. 7.4 9.1 vs. 20.5‡‡ 2.1 vs. 2.3
TAXUS-V (87,88) PES (n  577) vs.
BMS (n  579)
Complex lesions 9 0.49 vs. 0.90 13.7 vs. 31.9 15.0 vs. 21.2¶††‡‡ 0.5 vs. 0.9†† 5.4 vs. 4.6 8.6 vs. 15.7¶‡‡ 0.7 vs. 0.7**
60 NA NA NA 10.2 vs. 8.5 9.3 vs. 5.6¶ 17.0 vs. 23.2¶‡‡ 2.4 vs. 1.5¶
TAXUS-VI (89,90) PES (n  219) vs.
BMS (n  227)
Long complex
lesions
9 0.39 vs. 0.99 9.1 vs. 32.9 16.4 vs. 22.5 0.0 vs. 0.9†† 8.2 vs. 6.2 6.8 vs. 18.9 0.5 vs. 0.9**
60 NA NA 31.3 vs. 27.8#†† 2.8 vs. 3.2†† 11.2 vs. 8.2 14.6 vs. 21.4¶ 0.9 vs. 0.9**
HORIZONS-AMI
(91,92)
PES (n  2,257) vs.
BMS (n  749)
STEMI 13*/12† 0.41 vs. 0.82 8.2 vs. 21.0 8.0 vs. 7.9§§ 3.5 vs. 3.5 3.6 vs. 4.4 4.3 vs. 7.2¶‡‡ 3.1 vs. 3.3
24 NA NA 11.0 vs. 11.2§§ 4.3 vs. 5.2 5.7 vs. 6.1 6.8 vs. 11.6‡‡ 4.1 vs. 4.1
PASEO (57,58) PES (n  90) vs.
BMS (n  90)
STEMI 12 NA NA 11.1 vs. 24.4¶ 4.4 vs. 6.7 3.3 vs. 6.7 4.4 vs. 14.4¶ 1.1 vs. 1.1
48 NA NA 21.1 vs. 36.7¶ 8.9 vs. 12.2 7.8 vs. 13.3 6.7 vs. 21.1¶ 1.1 vs. 2.2
PASSION (93,95) PES (n  310) vs.
BMS (n  309)
STEMI 12 NA NA 8.8 vs. 12.8††‡‡ 4.6 vs. 6.5 1.7 vs. 2.0 5.3 vs. 7.8 1.4 vs. 2.3
60 NA NA 18.3 vs. 22.0††‡‡ 8.9 vs. 11.5†† 6.5 vs. 4.3 7.3 vs. 10.5 3.9 vs. 3.4
Erglis et al. (96) PES (n  53) vs.
BMS (n  50)
UPLMS 6 0.22 vs. 0.60 5.7 vs. 22.0¶ 13.2 vs. 30.0 1.9 vs. 2.0 9.4 vs. 14.0 1.9 vs. 16.0¶ 0.0 vs. 0.0
Differences are nonsignificant unless stated. Stent thrombosis as per Academic Research Consortium definition, unless indicated. All trial acronyms are listed in the Online Appendix. *Angiographic follow-up. †Clinical follow-up. ‡Major adverse cardiovascular events a
composite of death, MI, TVR, and ST. §Percutaneous revascularization only. p 0.001. ¶p 0.05. #Major adverse cardiovascular events a composite of death, MI, and TVR. **Protocol-defined ST. ††Cardiac death. ‡‡Ischemia driven. §§Major adverse cardiovascular events
a composite of death, MI, stroke, and ST. Definite ST only.
UPLMS  unprotected left main stem; other abbreviations as in Tables 2 and 3.
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August 31, 2010:S1–42 Coronary Stents: Current Status.5%, p  0.002) and 3-year follow-up (2.9% vs. 10.4%,
 0.01). Moreover, at 3-year follow-up, the use of the
iberté stent led to a 78% reduction in cardiac death (1.5% vs.
.7%, p 0.03), with no reported stent thrombosis (ST) (101).
ES versus PES. Several randomized studies, which are
ummarized in Table 5, have formally compared outcomes
etween patients treated with SES or PES for: 1) unselected
atients populations; 2) specific patient groups such as
iabetic patients or patients with STEMI; and 3) specific
esion types such as UPLMS lesions, long lesions, or lesions
n small vessels (102–117). Of note, results at short-term
ngiographic follow-up demonstrate superior reductions in
ate loss and binary restenosis with the use of SES; however,
ong-term angiographic follow-up, which is limited to the
IRTAX (Sirolimus Eluting Versus Paclitaxel Eluting
tents for Coronary Revascularization) study, indicates a
reater delayed late loss with SES in that, at 5 years, there
as no longer a significant difference in late loss between
ES and PES (107). With respect to clinical outcomes, a
eta-analysis of 16 randomized trials of SES versus PES,
hich included 8,695 patients and, where possible, patient-
evel data, reported significant reductions in TLR (hazard
atio [HR]: 0.74, 95% confidence interval [CI]: 0.63 to
.87, p  0.001) and ST (HR: 0.66, 95% CI: 0.46 to 0.94,
 0.02) with SES, whereas no significant differences in
eath (HR: 0.92, 95% CI: 0.74 to 1.13, p  0.43), or MI
HR: 0.84, 95% CI: 0.69 to 1.03, p  0.10) were noted at
median of 2-year follow-up (118).
ngiographic measures of DES effectiveness. As sug-
ested by the discussion in the preceding text, angiographic
A
C
TAXUS Express
Figure 6 TAXUS Express and TAXUS Liberté Stents
(A and B) The difference in stent strut distribution between the TAXUS Express an
Computer simulations illustrating the more uniform drug distribution achieved with
red indicates areas of high paclitaxel concentration. Image courtesy of Boston Scieasures such as late lumen loss and binary angiographic 0tenosis are commonly used surrogates of clinical effective-
ess in DES trials (119). Of the 2, binary angiographic
tenosis appears a more favorable variable as it requires a
ingle measurement and not, as in the case of late loss, 2
eparate measurements several months apart. In addition,
he relationship between late loss and TLR is dependent on
essel size, with more late loss being accommodated in
arger vessels before triggering a TLR (so-called headroom);
onversely, binary angiographic stenosis is independent of
essel size (120).
The relationship between late loss and the risk of binary
estenosis has been described as monotomic; in other words,
ncremental changes in late loss are associated with a
redictable increased risk of binary restenosis (121). Con-
ersely, a curvilinear relationship has been described be-
ween late lumen loss and TLR, namely, the increased risk
f TLR is not linear over the entire range of late lumen loss
122). Using data from the TAXUS IV trial, Ellis et al.
122) demonstrated that the normally low risk of TLR is
nly significantly increased once late lumen loss reaches a
hreshold 0.5 to 0.6 mm. This nonlinear relationship
erves to explain why significant differences in late loss
uring follow-up do not invariably translate into differences
n clinical outcomes. For example, in the REALITY (Com-
arison of the Cypher Sirolimus Eluting and the Taxus
aclitaxel Eluting Stent Systems Trial), the significantly
igher late lumen loss at 8 months with PES (PES vs. SES:
.31 mm vs. 0.09 mm, p 0.001) did not translate into any
ignificant difference in restenosis rate (PES 11.1% vs. SES
.6%, p  0.31) or TLR (PES 6.1% vs. SES 6.0%, p 
TAXUS Liberté
S Liberté stents. Reproduced with permission from Turco et al. (99). (C and D)
XUS Liberté stent. Blue indicates areas of low paclitaxel concentration, whereas
Natick, Massachusetts.B
D
d TAXU
the TA
entific,.99) at 12 months (105). Moreover, because of this
Summary of Major Randomized Trials (>100 Patients in Each Group) Comparing SES to PES in Different Clinical SettingsTable 5 Summary of Major Randomized Trials (>100 Patients in Each Group) Comparing SES to PES in Different Clinical Settings
Trial (Ref. #) No. of Patients Clinical Setting
Follow-Up,
Months
In-Stent
Late Loss
(SES vs. PES), mm
Binary In-Stent
Restenosis
(SES vs. PES), %
MACE
(SES vs. PES), %
Death
(SES vs. PES), %
MI
(SES vs. PES), %
TLR
(SES vs. PES), %
Definite/Probable ST
(SES vs. PES), %
DES-DIABETES
(102,103)
SES (n  200) vs.
PES (n  200)
Diabetic
patients
9 0.13 vs. 0.53* 3.4 vs. 18.2* 2.0 vs. 8.0† 0.0 vs. 0.5 0.5 vs. 0.5 2.0 vs. 7.5† 0.5 vs. 0.0
24 NA NA 3.5 vs. 12.5† 0.0 vs. 1.5 0.5 vs. 1.0 3.5 vs. 11.0† 1.0 vs. 0.0
ISAR-DIABETES
(104)
SES (n  125) vs.
PES (n  125)
Diabetic
patients
9 0.19 vs. 0.46* 4.9 vs. 13.6† NA 3.2 vs. 4.8 4.0 vs. 2.4 6.4 vs. 12.0 0.0 vs. 0.1
REALITY (105) SES (n  701) vs.
PES (n  685)
Unselected 8‡/12§ 0.09 vs. 0.31* 7.0 vs. 8.3 10.7 vs. 11.4 2.3 vs. 1.3 5.1 vs. 6.0 6.0 vs. 6.1 0.7 vs. 1.9¶
SIRTAX
(106,107)
SES (n  503) vs.
PES (n  509)
Unselected 8‡/9§ 0.12 vs. 0.25* 3.2 vs. 7.5† 6.2 vs. 10.8†# 1.0 vs. 2.2 2.8 vs. 3.5 4.8 vs. 8.3†# 2.0 vs. 1.8
60 0.30 vs. 0.37 NA 21.3 vs. 24.2 10.9 vs. 9.4 6.6 vs. 6.9 14.9 vs. 17.9 4.6 vs. 4.1
SORT-OUT II
(108)
SES (n  1,065) vs.
PES (n  1,065)
Unselected 18 NA NA 10.0 vs. 11.6** 3.8 vs. 3.9 4.2 vs. 5.1 4.5 vs. 5.9 2.6 vs. 2.8
TAXi (109,110) SES (n  102) vs.
PES (n  100)
Unselected 6 NA NA 6.0 vs. 4.0 0.0 vs. 0.0 2.0 vs. 3.0 2.0 vs. 1.0 1.0 vs. 0.0¶
36 NA NA 17 vs. 11 7.0 vs. 3.0 3.0 vs. 6.9 5.0 vs. 1.0 2.0 vs. 2.0¶
PROSIT
(111,112)
SES (n  154) vs.
PES (n  154)
STEMI 6‡/12§ 0.19 vs. 0.43† 5.0 vs. 12.0 5.8 vs. 11.7 (ST) 3.2 vs. 5.8 0.0 vs. 1.9 2.6 vs. 6.5 0.0 vs. 1.3¶
36 NA NA 12.3 vs. 18.8** (ST) 6.5 vs. 10.4 2.6 vs. 3.9 3.9 vs. 8.4** 0.6 vs. 1.9
ISAR-LEFT MAIN
(113)
SES (n  305) vs.
PES (n  302)
UPLMS 6–8‡/24§ NA 19.4 vs. 16.0 20.6 vs. 21.3 8.7 vs. 10.4 4.6 vs. 5.4 10.7 vs. 9.2 1.0 vs. 0.3
LONG-DES II
(114)
SES (n  250) vs.
PES (n  250)
Long lesions 6 0.09 vs. 0.45* 2.9 vs. 11.7† 12.0 vs. 17.2 0.8 vs. 0.0 8.8 vs. 10.8 2.4 vs. 7.2† 0.8 vs. 0.0¶
ISAR-SMART 3
(115)
SES (n  180) vs.
PES (n  180)
Small vessels,
nondiabetic
6–8‡/12§ 0.25 vs. 0.56* 8.0 vs. 14.9† 5.0 vs. 5.6 (Death/MI) 1.7 vs. 2.2 3.9 vs. 3.3 6.6 vs. 14.7† 0.0 vs. 0.0 (30 days)
ISAR-DESIRE
(116)
SES (n  100) vs.
PES (n  100)
In-stent
restenosis
6 0.10 vs. 0.26† 11.0 vs. 18.5 NA 2.0 vs. 1.0 1.0 vs. 2.0 8.0 vs. 19.0†** NA
ISAR-DESIRE 2
(117)
SES (n  225) vs.
PES (n  225)
SES in-stent
restenosis
6–8‡/12§ 0.40 vs. 0.38 19.0 vs. 20.6 20.4 vs. 19.6 3.4 vs. 4.5 2.7 vs. 1.8 16.6 vs. 14.6 0.4 vs. 0.4††
Differences are nonsignificant unless indicated. Stent thrombosis Academic Research Consortium definition unless indicated. All trial acronyms are listed in the Online Appendix. *p  0.001. †p  0.05. ‡Angiographic follow-up. §Clinical follow-up. Cardiac death.
¶Protocol-defined ST. #Ischemia driven. **Target vessel revascularization. ††Definite only.
Abbreviations as in Tables 2, 3, and 4.
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August 31, 2010:S1–42 Coronary Stents: Current Statuselationship, late lumen loss is regarded as having only
imited use in isolation in the assessment of clinical effec-
iveness among different DES, particularly if absolute levels
re low.
enefits of DES. Extensive data exist confirming the
enefits of DES in terms of reduced rates of restenosis
ompared with BMS. Results from the largest meta-analysis
o date, which included 18,000 patients from 38 DES
rials, indicated a reduction in TLR of 70% (p  0.0001)
ith the use of SES, and 58% (p  0.001) with the use of
ES, when compared with BMS out to 4 years of follow-up
Table 3) (22). This corresponded to a number needed to
reat, to prevent a single revascularization, of only 7 and 8
atients for SES and PES, respectively. Several other similar
eta-analyses have also been performed, and their results
re summarized in Table 3 (23–26).
Importantly, these impressive results are not only con-
ned to the select patients treated for on-label indications,
ut also have consistently been reproduced in registries and
andomized controlled trials that have included those with
atients receiving DES for off-label indications (76,78,123).
f note, a recent large meta-analysis by Kirtane et al. (76) that
ncluded 9,000 patients suggests that the benefit in terms of
educed restenosis from DES use appears to be at least as great
s in patients treated for off-label indications (HR: 0.46, 95%
I: 0.34 to 0.52, p  0.01) as opposed to on-label indications
HR: 0.54, 95% CI: 0.48 to 0.62, p  0.01).
isks of DES. MORTALITY. The concerns that DES in-
reased mortality stemmed from the presentation and pub-
ication of 4 studies. 1) A meta-analysis performed by
ordmann et al. (31) using aggregate trial data from 17
andomized studies of patients treated with SES, PES, and
MS that demonstrated a statistically significant increase in
oncardiac mortality between 2 and 3 years after SES
mplantation. 2) The single-center BASKET-LATE (Basel
tent Kosten Effektivitats Trial), which randomly assigned
46 unselected patients to either SES or BMS, and reported
higher rate of death and MI between 7 and 18 months
fter the index PCI among patients treated with SES
ompared with BMS (adjusted HR: 2.2, p  0.03). No
ignificant difference was seen in the rates of ST or
hrombosis-related events between groups; however, ulti-
ately the study was underpowered to detect ST events, and
imited angiographic evidence was available to confirm that
vents were actually due to ST (124). 3) The pooled analysis
f published data from the Cypher SES trials, RAVEL,
IRIUS, E-SIRIUS (European-Sirolimus-Eluting Stent in
e-Novo Native Coronary Lesions), and C-SIRIUS
Canadian-Sirolimus-Eluting Stent in De-Novo Native
oronary Lesions) by Camenzind et al. (32), that showed a
tatistically significant 2.4% increased risk of death and
-wave MI with the use of SES compared with BMS (6.3%
s. 3.9%, p  0.03). Much criticism was directed at the use
f the peculiar end point of death and Q-wave MI, and the
se of aggregate trial data. A subsequent analysis of the
ame studies by Spaulding et al. (23) using patient-level data endicated that there were no significant differences in
eath/MI between groups (11.4% SES vs. 10.1% BMS, p
.4). 4) The 3-year results of SCAAR (Swedish Angiogra-
hy and Angioplasty Registry), which reported results from
20,000 patients treated with BMS or DES between 2003
nd 2004, and demonstrated a higher overall risk of death
or patients receiving DES (adjusted relative risk [RR]: 1.18;
5% CI: 1.04 to 1.35) (33). Subsequent extended analyses to
ncorporate data from 2005, however, demonstrated a 31%
eduction in events during the first 6 months with DES, and
o difference in events between DES and BMS during
ong-term follow-up. That may have been the result of DES
se increasing from 22% to 53% of PCI procedures from 2003
o 2005, together with operators traversing the learning curve
ith DES, and thereby selecting lesions and patients more
ppropriately, and being more meticulous with ensuring ade-
uate stent deployment, and compliance to DAPT (125).
ost recently, data from the registry, extended to include new
atients treated in 2006 and now including just under 48,000
atients, showed a similar long-term incidence of death or MI
mong DES and BMS patients. Moreover, DES were also
hown to have a reduced rate of restenosis among high-risk
atients (125,126).
In the aftermath of these studies, which caused wide-
pread concern, several patient-based meta-analysis were
erformed that reassuringly demonstrated the overall com-
arable outcomes between DES and BMS in terms of death
nd MI, at both short- and long-term follow-up (Table 3).
he largest of these studies, by Stettler et al. (22), reported
similar risk of death for patients treated with SES, PES,
r BMS; the risk of MI, although comparable between PES
nd BMS (p  0.99), was significantly lower with SES
ompared with BMS (p  0.03) (22). Additional meta-
nalyses were performed at a similar time by Stone et al.
24), Spaulding et al. (23), Kastrati et al. (26), and Mauri et
l. (25), and now more recently by Kirtane et al. (76). All
eiterated the safety of DES by demonstrating the absence
f any significantly increased risk of death and/or MI with
he use of DES compared with BMS.
In addition to the data from randomized controlled trials,
bservation data comparing DES to BMS have been pub-
ished from numerous registries, which in total include
400,000 patients. The largest single registry published to
ate includes 262,700 patients from the Medicare registry
nd demonstrates lower rates of adjusted and unadjusted
eath, MI, and repeat revascularization after treatment with
ES compared with BMS out to 30 months of follow-up
123). A similar advantage in favor of DES was also
eported by Kirtane et al. (76) in a meta-analysis of 30
egistries, which included 180,000 patients followed up
or 12 to 48 months. These data reflect some of inherent
ifferences between randomized studies and observation
tudies, which provide a better reflection of real-world
ractice and, owing to the large numbers of patients
ecruited, may be able to detect differences in infrequent
vents. Conversely, however, they can be affected by a
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Coronary Stents: Current Status August 31, 2010:S1–42election bias and/or incomplete risk adjustment due to
nmeasured baseline population differences, factors that
ay account for the previously noted reductions in mortality
nd MI.
ff-label indications. The current on-label indications for
ES use, as approved by the U.S. FDA are limited to
imple lesions: for SES, de novo lesions 30 mm in length
n native coronary arteries with reference vessel diameters of
.5 to 3.5 mm, and for PES de novo lesions 28 mm in
ative coronary arteries 2.5 to 3.75 mm in diameter. It
ollows that off-label indications represent a higher-risk
opulation with more complex lesion morphologies and
nstable clinical presentations.
One of the criticisms of early DES trials was that they
nrolled stable patients treated with DES for on-label
ndications. For example, the meta-analyses by Stettler et al.
22), Stone et al. (24), Spaulding et al. (23), Kastrati et al.
26), and Mauri et al. (25) included patients who were
reated for essentially stable de novo lesions, which had a
ean lesion length of 23 to 24 mm, a mean vessel diameter
f 2.7 mm, and were suitably treated with an average of 1.2
o 1.4 stents. There were concerns that the comparative
esults between DES and BMS seen in these studies did not
eflect real-world practice in which 70% to 75% of DES are
mplanted for off-label indications (127,128).
Unfortunately, the lack of any dedicated trials comparing
ff-label DES and BMS added to these concerns, and the
DA Circulatory System Devices Advisory Panel that met
n December 2006 concluded that there was a need for a
omprehensive assessment of the safety and efficacy of
ff-label DES use (129). This prompted numerous studies,
any of which were observational, that ultimately demon-
trated that the use DES for off-label indications was
ssociated with poorer clinical outcomes in terms of death,
I, and repeat revascularization when compared with DES
se for on-label indications (127,130–132). Of equal im-
ortance are the results from registries and randomized
Figure 7 Stent Thrombosis
(A) Drug-eluting stent implantation in the proximal left anterior descending artery,
occurring 7 months later, shortly after discontinuation of dual antiplatelet therapy.ontrolled trials that suggest that, for off-label indications, rhe use of a DES is no worse than the use of a BMS
76,133–136), with some studies, such as the Medicare and
TENT (Strategic Transcatheter Evaluation of New Ther-
pies) registry actually demonstrating significantly improved
utcomes with the use of a DES (123,131). These findings
uggest that the overall poor outcome with off-label use is
ost likely related to patient or lesions characteristics, rather
han to specific shortcomings of DES.
T. ST has emerged as 1 of the major safety concerns with
tenting in today’s clinical practice (Fig. 7). Fortunately, it is
rare, but it remains a devastating unpredictable event that
as a significant morbidity and mortality (137); the clinical
onsequences are highly dependent on the myocardial area
t risk, its viability, the degree of recruitable collaterals, and
he speed of reperfusion therapy. The overall prognosis from
T is poor: 10% to 30% of patients with definite ST will die,
hereas a proportion will experience an unexpected out-of-
ospital death.
Early anecdotal reports of ST occurring in the months
nd years after implantation of a DES (138–140) were
ubstantiated by subsequent studies reporting an annual risk
f ST ranging from 0.2% in post-marketing surveillance
egistries, to 0.5% in trials of multivessel PCI (141–144).
he infrequent nature of ST, together with concerns re-
arding mortality among patients treated with DES, lead to
arge collaborative meta-analyses, performed using the stan-
ardized Academic Research Consortium (ARC) defini-
ions, that demonstrated similar rates of overall ST between
ES and BMS (Table 6) (22–26,145). In particular, no
ifference between DES and BMS was seen for early ST
30 days) or late ST (30 days to 1 year); however,
ignificantly higher rates of very late ST (1 year) were seen
ith DES. Furthermore, registry data from the Rotterdam-
ern group (n  8,146), the SCAAR (Swedish Angiogra-
hy and Angioplasty Registry) registry (n  21,717), and
he Pinto Slottow et al. registry (n  8,000) have all
ndicated that the risk of very late ST persists at an annual
icated by (B) stent thrombosis
ross pathology example of stent thrombosis.compl
(C) Gate of between 0.36% and 0.6%/year to at least 5 years after
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ollow-up from both the ARRIVE (The TAXUS Peri-
pproval Registry: AMulti-Centre Safety Surveillance) and
he STENT registry indicate that the risk of ST is higher
or patients treated with DES for off-label indications
ompared with on-label indications (130,131).
Uncertainty exists over the exact cause of ST; however,
umerous factors have been implicated in increasing the risk
f a ST event (Table 7). Of note, data from large-scale
egistries demonstrate that the multivariate predictors of ST
hange during follow-up (146,147,151,152). In addition to
he early cessation of DAPT, numerous other procedural-
elated factors such as stent undersizing, lesion length 28
m, dissection, multiple stent implantation, calcification,
nd small vessel diameter have been shown to be important
actors in the development of early/late but not very late ST
151,152). Conversely, patient factors such as previous
recipitants of Stent ThrombosisTable 7 Precipitants of Stent Thrombosis
Precipitant of Stent Thrombosis
Patient factors Percutaneous coronary intervention for acute coronary
syndrome/ST-segment elevation myocardial
infarction
Diabetes mellitus
Renal failure
Impaired left ventricular function
Premature cessation of dual anti-platelet therapy
Clopidogrel nonresponsiveness
Prior brachytherapy
Lesion characteristics Lesion/stent length
Vessel/stent diameter
Complex Lesions (bifurcation lesions, chronic total
occlusions)
Procedural factors Inadequate stent expansion
Incomplete stent apposition
Stent deployment in necrotic core
Device factors Hypersensitivity to drug coating or polymer
Incomplete endothelialization
ates of Overall, Early, Late, and Very Late Stent Thrombosis FromTable 6 Rates of Overall, Early, Late, and Very Late Stent Thro
First Author (Ref. #) No. of Patients
Longest
Follow-Up, yrs
SES vs. BMS
Spaudling et al. (23)* 1,748 (878 SES, 870 BMS) 4
Stettler et al. (22)* 8,646 (4,643 SES, 4,003 BMS) 4
Stone et al. (24)‡ 1,748 (878 SES, 870 BMS) 4
Kastrati et al. (26)‡ 4,958 (2,486 SES, 2,472 BMS) 5
PES vs. BMS
Stettler et al. (22)* 8,330 (4,327 PES, 4,003 BMS) 4
Stone et al. (24)‡ 3,513 (1,755 PES, 1,758 BMS) 4
Mauri et al. (25)* 2,797 (1,400 PES, 1,397 BMS) 4
Other
Stettler et al. (22)* 8,970 (4,643 SES, 4,327 PES) 4
Roukoz et al. (145)‡ 10,727 (5.534 DES, 5,193 BMS) 5
ifference nonsignificant unless indicated. Stent thrombosis defined by *Academic Research Cou
Abbreviations as in Tables 2 and 3.rrachytherapy and renal failure appear to be more influential
n very late ST. This variation in the cause of ST may
xplain the relatively higher rates of early ST when com-
ared with late/very late ST. For example, in the Dutch
tent registry of 21,009 patients, 437 patient had docu-
ented ST of which 32.0%, 41.2%, 13.3%, and 13.5% was
ategorized as acute, subacute, late, and very late ST,
espectively (151).
Two of the most prominent device concerns with the use
f DES that deserve additional consideration are their
bility to potentially delay endothelialization and induce
ypersensitivity reactions through the presence of a drug
olymer.
MPAIRED ENDOTHELIALIZATION BY ANTIPROLIFERATIVE
RUGS. The antiproliferative properties of DES impair
nd/or delay endothelialization so that blood is exposed to
hrombogenic stent struts, potentially precipitating ST
138,153–156). Animal studies using scanning electron
icroscopy have previously demonstrated a greater area of
xposed stent struts with the use of DES (SES 3.08 mm2,
ES 3.54 mm2) compared with BMS (0.12 mm2) (157).
ore recently, human studies using optical coherency
omography have also demonstrated differences between
ifferent types of DES, with the second generation
otarolimus-eluting stent (ZES) having significantly lower
ates of uncovered stent struts when compared with SES at
oth overlapping sites (0.06% vs. 5.4%) and nonoverlapping
ites (0.03% vs. 8.7%) (158). Similar results have been
eported by Kim et al. (159), whereas Barlis et al. (160)
emonstrated a higher rate of near complete (95%) strut
overage in a stent with a biodegradable polymer when
ompared with a stent with a durable polymer (SES [89.3%
s. 63.3%, p 0.03]). Incomplete strut coverage can also be
emonstrated on angioscopy, and has been seen as late as 2
ears after implantation of SES (161,162). The restitution
f a healthy but not hyperproliferative endothelial lining
ent Meta-Analyses Comparing DES to BMSis From Recent Meta-Analyses Comparing DES to BMS
Overall ST,
ES vs. BMS
Early ST,
DES vs. BMS
Late ST,
DES vs. BMS
Very Late ST,
DES vs. BMS
.6% vs. 3.3% 0.5% vs. 0.5% 0.3% vs. 1.3%† 2.8% vs. 1.7%
HR: 1.00 HR: 1.02 HR: 1.14 HR: 1.43
.2% vs. 0.6% 0.5% vs. 0.1% 0.1% vs. 0.5% 0.6% vs. 0.0%†
HR: 1.09 — — 0.6% vs. 0.05%†
HR: 1.38 HR: 0.95 HR: 1.61 HR: 3.57
.3% vs. 0.9% 0.5% vs. 0.6% 0.2% vs. 0.1% 0.7% vs. 0.2%†
.2% vs. 3.5% 0.5% vs. 0.5% 0.9% vs. 0.9% 1.8% vs. 2.1%
HR: 0.71§ HR: 1.05§ HR: 0.68§ HR: 0.39§
.4% vs. 1.3% 0.8% vs. 0.9% 0.3% vs. 0.4% 0.7% vs. 0.1%†
nitions or †p  0.05. ‡study protocols. §SES vs. PES.Stent designRecmbos
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Coronary Stents: Current Status August 31, 2010:S1–42OLYMER. Conventionally, DES are coated with perma-
ent polymers that facilitate drug release and remain long
fter drug elution is complete. These permanent polymers
an cause delayed healing, impaired stent strut endothelial-
zation, and a hypersensitivity reaction, which can culminate
n ST (153,157,163–165) Data from histopathology studies
lso indicate that these nonerodable polymers can precipi-
ate ST by inducing localized vascular inflammation, hy-
ereosinophilia, thrombogenic reactions, and apoptosis of
mooth muscle cells (164–166). Of note, the Cypher SES is
oated in a nonerodable poly(ethylene co-vinyl acetate) and
oly(n-butyl methacrylate) polymer that has been shown to
nduce granulomatous and hypersensitivity reactions in
nimal models and humans (167,168). Similarly, the first-
eneration TAXUS PES stent has a durable poly(styrene-
-isobutylene-b-styrene) polymer that is associated with
edial necrosis, positive remodeling, and excessive fibrin
eposition, which likely contribute to the deleterious patho-
ogic changes that can be seen with the TAXUS stent (168).
The potential of these first-generation stents to cause
T due to a permanent polymer has led to extensive
esearch into developing new polymers. These develop-
ents have led to the second-generation DES that have
ore biocompatible nonerodable polymers, which have
een shown in animal studies to have a greater degrees of
e-endothelialization compared with first-generation
tents (157). Research has also led to the design of the
ewer DES that are described in Part Two of this article,
nd have biodegradable polymers, novel coatings, or are
ompletely polymer free.
URATION OF ANTIPLATELET THERAPY. Although the
linical value and cost effectiveness of long-term clopidogrel
up to 12 months) with BMS after PCI for acute coronary
yndrome (ACS) is well established (169–171), the optimal
uration of DAPT after DES implantation remains an issue
f contention. Central to the discussion are repeated studies
hat demonstrate that premature (1 year) discontinuation
f DAPT is 1 of the most significant independent predictors
f ST (142,151,172,173), with poor patient compliance,
urgery, bleeding complications, poor patient education,
llergy to clopidogrel, and cost the most frequently cited
easons for cessation (146,172). It was this association
etween “early” discontinuation of DAPT and ST that led
uidelines’ authorities and the U.S. FDA advisory panel to
ecommend 12-month DAPT after DES implantation for
ll patients without contraindications and bleeding risk
128,174). However, these recommendations were made in
he absence of any prospective randomized trials evaluating
hether prolonged DAPT actually reduced rates of ST.
This association of cessation of DAPT and ST is com-
licated by studies that demonstrated that discontinuation
f clopidogrel is only a major independent predictor of ST
n the first 6 months after PCI, and not beyond. The
edian time interval for a ST event after the discontinua-ion of clopidogrel has been shown to be 9 days (interquar- (ile range 5.5 to 22.5) within the first 6 months of the PCI,
ompared with 104.3 days (interquartile range 7.4 to 294.8)
or the period after (173,175). Further complicating the
ssues are a lack of randomized data and reliance on
bservational studies, some of which indicate that discon-
inuing clopidogrel after 6 months does not increase the risk
f ST (175,176), whereas others demonstrate that long-
erm DAPT might be associated with reductions in death
nd MI (177,178). Other important facts to consider are
hat 1% of patients who discontinue DAPT experience a
T (179), whereas ST events commonly occur among
atients who are still receiving DAPT (173). For example,
n the Rotterdam-Bern study, 87% of patients with early ST
nd 23% of patients with late ST were still taking DAPT at
he time of the event (146). Further clouding matters is a
ossible hyperthrombotic rebound phenomena after clopi-
ogrel discontinuation. That has been suggested by, among
thers, Ho et al. (180), who observed a clustering of adverse
vents in the 90-day period after the cessation of clopidogrel
n 3,137 ACS patients who were treated either medically or
ith PCI.
Current registry data assessing long-term use of DAPT
how conflicting results. Park et al. (181) reported no benefit in
erms of reduced clinical outcomes or ST events in 2,851
atients treated with DES who received DAPT for 12
onths. More recently, however, the smaller TYCOON
Two-Year Clopidogrel Need Study) registry has reported
ore positive results among 443 patients treated with DES
ho received DAPT for 12 months (n 173) or 24 months
n  274). At 4-year follow-up, there was no difference in
linical outcomes; however, significantly lower rates of very
ate ST (2% vs. 0%, p  0.03) and overall ST (3% vs. 0.4%,
 0.02) were seen in the group receiving prolonged
APT. A major limitation of the study was failure to assess
he potentially adverse effects of prolonged DAPT in these
atients (182).
It is hoped that several on-going randomized trials will
rovide additional data to help establish the optimal dura-
ion of DAPT. The ISAR-SAFE (Intracoronary Stenting
nd Angiographic Results: Safety And Efficacy of 6 Months
ual Anti-platelet Therapy After Drug Eluting Stenting)
tudy and the OPTIMIZE (Optimized Duration of
lopidogrel Therapy Following Treatment With the
ndeavor Zotarolimus-Eluting Stent (ZES) in the
Real-World”) study are both currently randomizing
atients treated with DES to either standard therapy of
2 months of DAPT or shorter periods of DAPT ranging
rom 3 months (OPTIMIZE) or 6 months (ISAR-SAFE)
183,184). Conversely, the DAPT (Dual Anti-Platelet
herapy Trial) will compare outcomes of 20,000 patients
reated with BMS and DES who are randomly allocated to
APT therapy for either 12 or 30 months (185).
These concerns may be rendered immaterial if the initial
romise from newer antiplatelet agents, which have recently
een assessed in randomized controlled trials, is maintained
Fig. 8). Prasugrel represents a novel antiplatelet agent
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August 31, 2010:S1–42 Coronary Stents: Current Statushat is a more effective inhibitor of the P2Y12 platelet
denosine diphosphate receptor, compared with both
iclopidine and clopidogrel. This results in its antiplatelet
ctivity peaking 60 min after oral administration, com-
ared with 2 to 6 h with clopidogrel (186). In the recent
RITON–TIMI 38 (Trial to Assess Improvement in
herapeutic Outcomes by Optimizing Platelet Inhibition
ith Prasugrel–Thrombolysis In Myocardial Infarction
8) trial that randomized 13,000 patients with ACS, use
f prasugrel was associated with a significant reduction in
he primary end point (a composite of cardiac death/
onfatal MI/nonfatal stroke), and rates of MI, TVR, and
T (p  0.001 for all), when compared with standard
herapy with clopidogrel. Of note, the risk of major life-
hreatening and fatal bleeding was significantly higher with
rasugrel (187). A pre-specified substudy analysis involving
12,000 patients who received a stent reported significantly
educed rates of ST in patients receiving prasugrel (1.13%
Figure 8 Activation of Clopidogrel, Prasugrel, and Ticagrelor
Clopidogrel, prasugrel, and ticagrelor are all absorbed from the gut. Ticagrelor
is active immediately, and binds in a reversible fashion to the P2Y12 receptor
on the platelet. Prasugrel is first hydrolyzed by esterases, before undergoing
hepatic CYP-mediated oxidation to produce the active metabolite that binds
irreversibly to the P2Y12 receptor on the platelet for the duration of the plate-
let’s life. Clopidogrel requires 2 oxidation steps within the liver before binding
irreversibly to the P2Y12 receptor.s. 2.35%, HR: 0.80, p  0.03), with at least as great a Feduction in ST seen in patients treated with a DES (HR:
.36) compared with a BMS (HR: 0.52) (188).
Ticagrelor is a cyclopentyl triazolopyrimidine and func-
ions as an orally active reversible inhibitor of the platelet
denosine diphosphate receptor P2Y12. In the recently
ublished PLATO (Platelet Inhibition and Patient Out-
omes) study, use of ticagrelor compared with clopidogrel in
8,624 patients with ACS resulted in a 16.0% reduction in
he primary end point, which was a composite of death from
ascular causes, MI, or stroke (9.8% vs. 11.7%, HR: 0.84;
5% CI: 0.77 to 0.92; p  0.001). Moreover, rates of ST
mong patients receiving a stent were also significantly
ower in those treated with ticagrelor compared with clopi-
ogrel (1.3% vs. 1.9%, p  0.009). Rates of major bleeding
ere comparable; however, patients treated with ticagrelor
ad high rates of non-CABG–related major bleeding (4.5%
s. 3.8%, p  0.03), which included more instances of fatal
ntracranial bleeding (189,190). Conversely, patients treated
ith ticagrelor had a lower risk of CABG major bleeding,
hich is the likely consequence of its reversibility that
nables it to dissipate before surgery.
LOPIDOGREL RESISTANCE/NONRESPONDERS. In recent
imes, resistance to aspirin and/or clopidogrel, which may
ccur in as many as 44% of patients (191,192), has emerged
s a potential risk factor for adverse cardiac events, partic-
larly ST (193–195). The underlying mechanism of this
onresponsiveness is not completely understood, but is
ikely to occur through a combination of clinical, cellular,
nd genetic factors, together with potential drug interac-
ions (196).
The assessment of clopidogrel resistance has been ad-
anced after developments in patient tests. Importantly,
everal studies in patients undergoing elective or urgent PCI
ave reported a correlation between the reactive platelet
esponse to adenosine diphosphate, assessed using the
oint-of-care assay VerifyNow (Accumetrics, San Diego,
alifornia), and clinical outcomes ranging from periproce-
ural MI to 1-year MACE (197–201). These results indi-
ate the potential importance of platelet function testing;
owever, in the absence of large-scale clinical trials, these
ests can only be regarded as research tools at present.
Despite the potential to identify patients with clopidogrel
esistance, no definitive treatment has been fully established,
nd in view of the potentially fatal consequences, this
epresents a major clinical problem. Simple measures in-
lude ensuring adequate patient compliance and evaluating
ossible drug interactions. Additional strategies that have
een suggested include the following. 1) Use an increased
aintenance dose of clopidogrel of 150 mg/day, which may
mprove clinical outcomes without significantly increasing
leeding (202,203). This treatment for clopidogrel resis-
ance is currently being assessed in the randomized
RAVITAS (Gauging Responsiveness With A VerifyNow
ssay—Impact on Thrombosis and Safety) study (204).
urther anecdotal support for this strategy is provided by
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Coronary Stents: Current Status August 31, 2010:S1–42he PCI cohort in the randomized CURRENT–OASIS 7
Clopidogrel Optimal Loading Dose Usage to Reduce
ecurrent Events–Optimal Anti-platelet Strategy for Inter-
entions) study, which has recently reported the safety and
linical benefits of administering 150 mg/day clopidogrel for
days after PCI in patients with ACS or STEMI treated
efore PCI with a 600-mg loading dose of clopidogrel. The
se of the higher dose of clopidogrel led to significant
eductions in both definite ST and MI at 30-day follow-up,
ithout any significant increase in stroke or major, fatal, or
ABG-related bleeding (205,206). 2) Use additional anti-
latelet agents such as glycoprotein IIb/IIIa inhibitors
uring PCI, and cilostazol, a phosphodiesterase III inhibi-
or, during maintenance (207–209). 3) Use alternative
2Y12 receptor antagonists such as prasugrel or ticagrelor.
perator technique. The importance of operator tech-
ique in ensuring adequate stent deployment cannot be
verstated in maximizing the benefit and minimizing the
isk associated with stent implantation. Specifically, subop-
imal or incomplete stent expansion is associated with
ncreased rates of restenosis and TVR, and is a possible
recipitant of ST (16,151,210–212).
One of the most common causes of suboptimal stent
eployment is stent undersizing, which is aggravated by the
se of direct stenting, and by relying solely on coronary
ngiography to assess stent size together with the underuse
f intravascular ultrasound (IVUS). Previous studies dem-
nstrate that reference vessel diameters vary significantly
epending on the method of measurement used. For exam-
le, Briguori et al. (213) reported a difference between
VUS and angiography of 1.0 mm in 71% and 49% of
ases with vessel size diameters 2.75 mm and 2.75 mm,
espectively.
As alluded to, IVUS has an important role to play in
ptimizing stent implantation that extends beyond just
inimizing the risk of stent undersizing. Intravascular
ltrasound is considerably more accurate than angiography
n determining in-stent dimensions, identifying incomplete
tent apposition (ISA), and stent-edge dissections.
LINICAL IMPLICATIONS. Studies indicate that the main
linical consequences of stent underexpansion are restenosis,
T, and stent fracture.
ESTENOSIS. In BMS studies, minimum stent area was
dentified as the single most powerful predictor of in-stent
estenosis (ISR), with an inverse correlation between post-
rocedural minimum stent area and both angiographic
estenosis and TVR (214,215). After the arrival of DES and
he subsequent reduction in TVR, less importance was given
o adequate stent deployment. Importantly, observational
tudies have indicated that not only is minimum stent area
till an independent predictor of ISR in patients having
ES, but also that the rate of stent underexpansion with
ES may be as high as 30% (216–218). This finding
eiterates the importance of maximizing final minimal stent
rea/diameter with noncompliant balloon inflation, thereby seducing suboptimal stent deployment, which may result in
mproved clinical outcomes. Unfortunately, at present, no
andomized data exist investigating this with DES.
T. Minimum stent area and suboptimal stent expansion
epresent major post-procedural predictors of ST (211,219,220).
etrospective data from Fuji et al. (211) indicate that lesions
eading to ST after successful implantation of a SES stent
ore often have stent underexpansion, a small minimum
tent area, and a residual edge stenosis. The importance
f IVUS assessment after stent deployment is reaffirmed
y registry data from 7,000 patients treated with BMS
ndicating that only approximately one-fifth of patients
xperiencing subacute ST had an optimum PCI result as
ssessed by IVUS. Moreover, analysis of these throm-
osed stents indicates inadequate lumen dilation (final
umen 80% reference lumen), edge dissection, ISA, and
laque prolapse in 78%, 17%, 9%, and 4% of cases,
espectively (221).
Incomplete stent apposition can be acute if detected at
he time of the procedure, or late if detected at follow-up
Fig. 9) (222). Acute ISA can resolve itself, or if detected at
he time of stent implantation, can be treated immediately
ith balloon dilation. Late ISA can be persistent (present
fter procedure and at follow-up) or acquired, if only
etected on follow-up (223). Some studies (219) but not all
224,225) have suggested that ISA is associated with an
ncreased risk of ST. Moreover, a recent meta-analysis has
emonstrated that the risk of late acquired ISA is signifi-
antly higher for DES compared with BMS (OR: 4.36, 95%
I: 1.74 to 10.94), whereas the risk of late/very late ST is
Figure 9 Stent Malapposition
Stent malapposition is seen from the 11 o’clock to 9 o’clock position using
Fourier domain optical coherence tomography (Terumo Corp., Tokyo, Japan).
Reproduced with permission from Okamura et al. (222).ignificantly higher for patients with ISA when compared
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August 31, 2010:S1–42 Coronary Stents: Current Statusith patients who do not have ISA (OR: 6.51, 95% CI: 1.34
o 34.91) (226).
This difference in ISA between DES and BMS may be
ue to the effect of the antiproliferative drug on the vessel
all, causing positive remodeling, or a result of the decrease
n plaque volume behind the stent struts (227). It has also
een demonstrated using optical coherence tomography in
atients before PCI and at 9-month follow-up that lesions
ith plaque rupture, thrombus, lipid-rich plaque, and thin-
apped fibroatheroma have a greater incidence of ISA than
o patients not having those features at baseline (83% vs.
0%, p  0.001) (228).
It remains unclear exactly how ISA leads to ST. It may be
he result of chronic inflammation and delayed healing,
ausing tissue necrosis and erosion around the stent (153).
he link between inflammation, ISA, and ST has been
eaffirmed by a histopathology study of ST eosinophil
ounts demonstrating that not only is very late ST associ-
ted with a greater degree of inflammation than other types
f ST (early, late, BMS), but also eosinophil counts appear
o correlate with the degree of ISA (167). Finally, ISA may
erve as a trigger for thrombosis by allowing fibrin and
latelet deposition behind stent struts (229).
tent fracture. Stent fracture remains an uncommon late
omplication of DES implantation (230,231) whose true
ncidence among first-generation DES remains unknown;
owever, rates of 1% to 2%, 1% to 7.7%, and as high as 29%
ave been reported in randomized, observational, and au-
opsy studies, respectively (232–235). Notably, the majority
f stent fractures have been reported with the Cypher SES,
hereas stent fractures with TAXUS PES and BMS have
een seen very rarely. This difference may be related to the
ncreased radio-opacity of the Cypher SES, its closed cell
esign, and/or the greater neointimal coverage seen with the
ES and BMS that may strengthen and stabilize the struts
o withstand the mechanical forces that result in stent
racture. Overall, stent fractures can range from a single
trut fracture (grade I) through to multiple strut fractures
grade V).
There are a number of suspected causes for stent fractures
hat include both mechanical and lesion-based factors.
ECHANICAL FACTORS. Stent fracture may be the conse-
uence of an excessive mechanical vessel wall stress that
ccurs from extreme repetitive contraction and flexion of the
essel (233). Of note, this may actually be a protective
echanism for stress relief within the vessel.
ESION FACTORS. Predictors for stent fractures have in-
luded lesions located in the right coronary artery and/or
esions in very tortuous or severely calcified vessels. Addi-
ional factors increasing the risk of stent fracture include
mplantation of long and/or overlapping stents (Fig. 10),
nderlying diffuse disease, SVG, and treatment of CTO
230,235–237). In a recent autopsy study, longer stent
ength, use of the Cypher stent, and longer stent duration
ere all identified as independent predictors of stent frac-
ure (235). cPatients with stent fractures may remain asymptomatic;
owever, they may present with ACS, ST, or recurrent
ngina due to clinical restenosis; overall, 70% to 80% of
atients with a stent fracture will present with ISR or ST
230,231,233,238). The extent of symptoms appears to be
elated to the grade of the stent fracture, with few symptoms
ccurring as a result of grade I to grade IV stent factures,
hereas grade V stent fractures are associated with the most
dverse clinical events (235). There are no data on definitive
reatment; however, repeat PCI, which is the current
referred strategy, appears to provides prompt symptom
elief (230,231). Some suggest treatment using a short stent,
ogether with extending DAPT beyond 12 months (239).
oronary artery aneurysms. Coronary artery aneurysms
re a rare complication of stenting, whose true incidence,
linical course, and treatment are largely unknown (Fig. 11).
evertheless, studies report an incidence between 0.3% and
.0% after DES and BMS implantation (240). There are a
umber of postulated causes for these coronary artery
neurysms, some of which are specific for DES. In general,
echanical causes include the use of oversized balloons or
tents, high-pressure balloon inflations, and atherectomy—
ll of which can cause residual dissection and deep arterial
all injury eventually leading to aneurysm formation
241–243). Of note for DES, the elution of antiproliferative
rugs and/or presence of a polymer can lead to delayed
e-endothelialization, inflammatory changes in the medial
all, ISA, and hypersensitivity reactions, all of which can
esult in coronary artery aneurysm formation (240). Data on
oronary aneurysms are derived mainly from case reports
ndicating a variable clinical course that is similar irrespec-
ive of whether the aneurysm is after BMS or after DES
mplantation. In particular, aneurysms have been detected
rom as early as 3 days after DES implantation (244) and as
ate as 9 years after BMS implantation (245).
Coronary artery aneurysms can be associated with reste-
osis (246), whereas turbulent and sluggish blood flow in
he area of the aneurysm, coupled with a metallic stent, can
redispose patients to the risk of ST and/or distal emboli-
ation (247,248). Currently, there are no definitive data on
he best management of patients with coronary artery
neurysms, treatment of which is complicated by some
neurysms resolving spontaneously (249), whereas others
ead to life-threatening complications. In addition to the use
f long-term DAPT to minimize the risks of ST, therapeu-
ic options that can be considered include the use of coils
nd cardiac surgery.
econd-Generation DES
he initial coronary stents were composed of 316L stainless
teel since this material is radio-opaque and provides ade-
uate radial strength to maintain arterial scaffolding with
inimal acute recoil. An alternative to stainless steel is
obalt chromium (CoCr), which exhibits superior radial
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Coronary Stents: Current Status August 31, 2010:S1–42trength and improved radio-opacity, allowing for thinner
tent struts that may reduce restenosis (250–252). Thinner
truts can also lead to a reduction in device profile and,
ence, an improvement in stent deliverability to the target
esion. The 2 second-generation DES that are currently
pproved by the U.S. FDA utilize CoCr, and elute “limus”
rugs with the aid of more biocompatible polymers than are
ound on the first-generation DES.
ndeavor ZES. The second-generation Endeavor ZES
Medtronic, Minneapolis, Minnesota) uses the CoCr Driver
tent platform loaded with a permanent “biomimetic” phos-
horylcholine polymer (Table 1), which although not biode-
radable is biostatic and biocompatible, being a natural com-
onent of the cell membrane. The polymer, which releases
95% of the sirolimus analogue, zotarolimus, within 14 days
f stent deployment, causes less inflammation compared with
he polymers on the Cypher SES stent.
Both animal studies and in vivo studies using angioscopy
nd optical coherence tomography have shown a greater
ndothelial coverage of struts with ZES compared with SES
nd PES (157,253–255). Angioscopy has demonstrated
A
C
Figure 10 Stent Fracture
(A) A long, diffusely diseased left anterior descending artery is treated with 3 siro
ever, at (C) 3-months’ follow-up, an irregular appearance is seen, and is the resul
(red lines). Reproduced with permission from Popma et al. (236).evels of neointimal coverage with ZES that are superior to bhat SES and comparable to that seen with BMS (253).
imilarly, the mean percentage of covered struts seen by
ptical coherency tomography 3 months after implantation
f ZES, SES, and BMS has been reported in separate
tudies as 99.9%, 85%, and 99.9%, respectively (254,255).
Clinical data on ZES are available from the Real-World
-Registry, and from numerous other trials ranging from the
rst-in-man ENDEAVOR I study to randomized trials com-
aring ZES to BMS, SES, and PES (Table 8) (256–269).
ata from the “all-comers” E-Registry at 12 months of
ollow-up, and a pre-specified subgroup of patients who had
xtended follow-up for 2 years in the E-Five (Endeavor
tent Registry) study, demonstrate comparable outcomes
etween the randomized ENDEAVOR studies and real-
orld patients.
The superiority of ZES compared with BMS was demon-
trated in the 1,197-patient, randomized ENDEAVOR II
tudy, which reported significantly lower in-stent late loss and
ngiographic binary restenosis at 9-month follow-up with
ES, together with significantly lower TLR out to 5 years of
ollow-up. Rates of death, MI, and ST remained comparable
luting stents (white arrows). (B) The initial angiographic result is excellent; how-
) 4 stent fractures (black arrows) occurring adjacent to regions of stent overlapB
D
limus-e
t of (Detween both stents throughout follow-up (258,259).
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August 31, 2010:S1–42 Coronary Stents: Current StatusIn the comparison with other DES, data have indicated a
elatively poorer performance of ZES compared with PES and
ES at short-term follow-up, as indicated by significantly
igher late loss and numerically greater TLR (260,264).
esults at longer follow-up have been more reassuring after the
bserved reductions in the absolute difference in TLR between
ES and SES/PES. For example, in the ENDEAVOR III
tudy, the 2.8% absolute difference in TLR between ZES and
ES at 1 year was reduced to 1.6% at 5 years (260,262),
hereas in the ENDEAVOR IV study, the absolute difference
n TLR between ZES and PES was 1.3% and 0.5% at 1 year
nd 3 years, respectively (264,265). Although at only medium-
erm follow-up, these results suggest the absence of the
late-catch” phenomenon with ZES.
Conflicting results have been observed when comparing
ES to SES and PES for early and late ST; however,
espite this, a consistent benefit has been seen with ZES in
erms of reduced very late ST (Fig. 12). Although these
urrent trials are underpowered to detect differences in ST,
hese inconsistencies with ZES serve to reaffirm data that
ndicate the lack of association between in-stent late loss
nd ST (270); moreover, they reiterate the complex
athophysiology underlying ST. The only adequately
owered study that will provide definitive data on the
afety and efficacy between ZES and SES is the fully
nrolled PROTECT (Patient Related Outcomes With
ndeavor Versus Cypher Stenting Trial) study. This study
as randomly assigned 8,800 “all-comers” patients to treat-
ent with either the ZES or SES, and will report a primary
A
C
Figure 11 Coronary Artery Aneurysms
A coronary aneurysm (white arrows) is seen on (A) coronary angiography and on (
ultrasound. The aneurysm has led to extensive stent malapposition (B and C).nd point of definite/probable ST at 3-year follow-up (271). cience V everolimus-eluting stent (EES). The Xience V
ES (Abbott Vascular, Santa Clara, California) consists
f the Multilink Vision CoCr platform with a nonerod-
ble biocompatible polymer and 100 g/cm2 everolimus,
synthetic derivative of sirolimus (40-O-[2-hydroxyethyl]-
apamycin). The 6- to 8-m-thick polymer is composed of
crylic and fluorinated polymers and releases 80% of the
rug within 30 days, with nearly all the drug released within
months (Table 1). This stent is also marketed by Boston
cientific as the Promus stent. In the U.S., the Abbott supply
greement for the Promus stent continues until 2012 when the
romus stent will be replaced by the Promus Element stent.
Clinical data consist of both real-world registries, and
andomized trials comparing EES to BMS and PES.
esults have consistently demonstrated the safety and effi-
acy of the EES, together with low rates of ST out to
ong-term follow-up (Table 9) (272–282).
In brief, the randomized SPIRIT (Clinical Evaluation of
he Xience V Everolimus Eluting Coronary Stent System)
I, III, IV studies and the COMPARE (Second-
eneration Everolimus-Eluting and Paclitaxel-Eluting
tents in Real-Life Practice) study have all compared EES
nd PES. Two-year follow-up of the SPIRIT II study was
he first study to demonstrate “delayed” restenosis with
verolimus, a phenomenon previously observed with other
ES (283,284); however, this did not appear to have any
etrimental effect on clinical outcomes. In fact, at 3-year
ollow-up, a greater absolute difference in cardiac death, MI,
LR, and MACE in favor of EES was observed when
B
ss-sectional and (C) longitudinal intravascular
duced with permission from Alfonso et al. (246).B) cro
Reproompared with results at both 1- and 2-year follow-up
The Most Prominent Randomized Trials and Registries of the Second-Generation ZESTable 8 The Most Prominent Randomized Trials and Registries of the Second-Generation ZES
Trial (Ref. #) No. of Patients
Follow-Up,
Months
In-Stent Late
Lumen Loss
(ZES vs.), mm
Binary
In-Stent Restenosis
(ZES vs.), %
Death
(ZES vs.), %
Myocardial
Infarction
(ZES vs.), %
Target Lesion
Revascularization
(ZES vs.), %
TVF
(ZES vs.), %
Definite/Probable ST
(ZES vs.), %
Randomized trials
ENDEAVOR I
(256,257)
ZES (n  100) 12 0.61 5.4 0.0 1.0 2.0 2.0 1.0
60 — — 4.1 1.0 3.1 5.2 1.0
ENDEAVOR II
(258,259)
ZES (n  598) vs. BMS (n  599) 9 0.61 vs. 1.03* 9.4 vs. 33.5* 1.2 vs. 0.5 2.7 vs. 3.9 4.6 vs. 11.8*† 7.9 vs. 15.1* 0.5 vs. 1.2
60 — — 6.2 vs. 7.6 3.8 vs. 4.8 7.5 vs. 16.3*† 15.4 vs. 24.4* 0.9 vs. 1.7
ENDEAVOR III
(260,262)
ZES (n  323) vs. SES (n  113) 8‡/9§ 0.60 vs. 0.15* 9.2 vs. 2.1 0.6 vs. 0.0 0.6 vs. 3.5 6.3 vs. 3.5† 12.0 vs. 11.5 0.0 vs. 0.0
60 — — 5.2 vs. 13.0 1.0 vs. 4.6 8.1 vs. 6.5† 17.9 vs. 18.5 0.7 vs. 0.9
ENDEAVOR IV
(264,265)
ZES (n  773) vs. PES (n  775) 8‡/12§ 0.67 vs. 0.42* 13.3 vs. 6.7 1.1 vs. 1.1 1.6 vs. 2.7 4.5 vs. 3.2† 6.6 vs. 7.2¶ 0.9 vs. 0.1
36 — — 4.0 vs. 4.5 2.2 vs. 4.9 6.5 vs. 6.0† 12.4 vs. 16.1 1.1 vs. 1.6
ZEST (266) ZES (n  880) vs. SES (n  880) vs.
PES (n  880)
12 — — 0.7 vs. 0.8 vs. 1.1 5.3 vs. 6.3 vs. 7.0 4.9 vs. 1.4 vs. 7.5* — 0.7 vs. 0.0 vs. 0.8
SORT-OUT III (267) ZES (n  1,162) vs. SES (n  1,170) 9 — — 2.0 vs. 2.0 1.4 vs. 0.5 4.0 vs. 1.0*† — 1.1 vs. 0.2#
18 — — 4.4 vs. 2.7 2.1 vs. 0.9 6.1 vs. 1.7*† — 1.1 vs. 0.5#
Registry data
E-Registry (268) ZES (n  7,832) 12 — — 2.4 1.6 4.5 7.2 1.1
E-Five Registry (269) ZES (n  2,116) 12 — — 1.7 1.2 4.5 6.7 0.6
24 — — 2.9 1.5 5.1 7.9 0.7
Differences nonsignificant unless indicated. All trial acronyms are listed in the Online Appendix. *p  0.001. †Ischemia-driven. ‡Angiographic follow-up. §Clinical follow-up. p  0.05. ¶p  0.001 for noninferiority. #Definite only.
ST  stent thrombosis; TVF  target vessel failure (a composite of cardiac death, target vessel myocardial infarction, or target vessel revascularization); ZES  zotarolimus-eluting stent; other abbreviations as in Tables 2 and 3.
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August 31, 2010:S1–42 Coronary Stents: Current StatusFig. 13) (275). Similarly, in the larger SPIRIT III study,
he benefit of EES over PES increased during follow-up,
nd at 3 years, use of EES lead to significant reductions in
arget vessel failure, target lesion failure, and MACE (278).
ecently, 2 important randomized studies assessing EES
ave reported 12-month outcomes. The SPIRIT IV study,
hich enrolled 3,690 patients, represents the largest ran-
omized trial comparing 2 DES; and the COMPARE
tudy, which recruited 1,800 patients, was the first random-
zed all-comers trial of the EES (279,281). Both studies
emonstrated significantly superior efficacy and safety with
ES compared with PES. In addition, whereas nonsignifi-
antly lower rates of ST have been observed in the SPIRIT
Figure 12 Rates of Stent Thrombosis Comparing ZES to SES o
Rates of early/late and very late definite/probable stent thrombosis in randomized
sirolimus-eluting stent (SES [red bars]) or paclitaxel-eluting stent (PES [green bars
conversely, very late stent thrombosis rates are consistently lowest with ZES. No d
he Most Prominent Randomized Trials and Registries of the SeconTable 9 The Most Prominent Randomized Trials and Registries
Trial (Ref. #) No. of Patients
Follow-Up,
Months
In-Stent Late
Lumen Loss
(EES vs.), mm
Binary
In-Stent
Restenos
(EES vs.),
SPIRIT FIRST
(272,273)
EES (n  27) vs.
BMS (n  29)
6 0.10 vs. 0.87* 0.0 vs. 25.
60 — —
SPIRIT II
(274,276)
EES (n  223) vs.
PES (n  77)
6 0.11 vs. 0.36* 1.3 vs. 3.5
48 — —
SPIRIT III
(277,278)
EES (n  669) vs.
PES (n  333)
8§/12 0.16 vs. 0.30† 2.3 vs. 5.7
36 — —
SPIRIT IV (279) EES (n  2,458) vs.
PES (n  1,229)
12 — —
SPIRIT V (280) EES (n  2,663) 12 — —
24 — —
COMPARE
(281)
EES (n  897) vs.
PES (n  903)
12 — —ifferences nonsignificant unless indicated. All trial acronyms are listed in the Online Appendix. *p  0.0
EES  everolimus-eluting stent(s); other abbreviations as in Tables 2 and 3.I and III studies, the SPIRIT IV and COMPARE studies
ere the first to demonstrate a significant reduction in ST
etween 2 DES. At 12-month follow-up, rates of definite/
robable ST for EES and PES were 0.29% versus 1.06%
p  0.003), and 0.7% versus 2.6% (p  0.002) in the
PIRIT IV and COMPARE studies, respectively.
Some have suggested that the superiority of EES has only
een demonstrated because it has not been compared with
he SES, which historically is regarded as the most effica-
ious first-generation DES (22,105,106). Important data on
his issue will be provided by the EXCELLENT (Efficacy
f Xience/Promus Versus Cypher in Reducing Late Loss
fter Stenting) study, which plans to randomize 1,400
comparing the Endeavor zotarolimus-eluting stent (ZES [blue bars]) to either the
tes of early/late stent thrombosis are consistently higher with the ZES; however,
ces are significant. ARC  Academic Research Consortium.
neration EESe Second-Generation EES
Death
EES vs.), %
Myocardial
Infarction
(EES vs.), %
Target Lesion
Revascularization
(EES vs.), %
MACE
(EES vs.), %
Definite/
Probable ST
(EES vs.), %
0.0 vs. 0.0 3.8 vs. 0.0 3.8 vs. 21.4‡ 7.7 vs. 21.4 0.0 vs. 0.0
0.0 vs. 7.4 8.3 vs. 0.0 8.3 vs. 28.0‡ 16.7 vs. 28.0 0.0 vs. 0.0
0.0 vs. 1.3 0.9 vs. 3.9 2.7 vs. 6.5 2.7 vs. 6.5 0.5 vs. 1.3
4.9 vs. 9.9 3.6 vs. 7.5 5.9 vs. 12.7 7.7 vs. 16.4 1.0 vs. 3.0
1.2 vs. 1.2 2.8 vs. 4.1 3.4 vs. 5.6 6.0 vs. 10.3† 1.1 vs. 0.6
2.6 vs. 4.1 3.7 vs. 6.3 5.4 vs. 8.9‡ 9.1 vs. 15.7† 1.3 vs. 1.7
1.0 vs. 1.3 1.9 vs. 3.1† 2.5 vs. 4.6†‡ 4.2 vs. 6.9*‡ 0.3 vs. 1.1†
1.7 3.5 1.9 5.3 0.65
3.0 4.4 3.0 7.5 0.79
2.0 vs. 1.6 2.8 vs. 5.3† 2.0 vs. 5.3* 6.2 vs. 9.1† 0.7 vs. 2.6†r PES
trials
]). Ra
ifferend-Geof th
is
% (
9†01. †p  0.05. ‡Ischemia driven. §Angiographic follow-up. Clinical follow-up.
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Coronary Stents: Current Status August 31, 2010:S1–42atients to treatment with either EES or SES (285). The
tudy will also investigate the optimal duration of DAPT by
omparing outcomes in patients randomly assigned to 6
onths or 12 months of DAPT.
The Xience PRIME EES, which represents the latest
evelopment of the Xience V stent, has recently gain regulatory
pproval in Europe. This modified EES has a CoCr platform;
owever, this is mounted on a new enhanced stent delivery
ystem that enables the stent to be more flexible and deliver-
ble. Furthermore, the stent balloon has higher rate burst
ressures, and shorter balloon tapers to minimize the risk of
dge dissections. The stent is being evaluated in the prospec-
ive, multicenter, nonrandomized SPIRIT PRIME study in
00 patients at 75 hospital centers, with the aim of gaining
.S. FDA approval.
ssues of Today
ole of BMS in Contemporary Practice
espite the benefits of DES, there is still a role for BMS in
Figure 13 Clinical Outcomes in the SPIRIT II Trial
The delayed restenosis observed with the XIENCE V everolimus-eluting stent (EES
difference in (A) cardiac death, (B) myocardial infarction (MI), (C) ischemic target
(MACE) seen between EES and the TAXUS paclitaxel-eluting stent (PES [red lines]
larger absolute difference between both stents was observed at 3-year follow-up. Rhe management of patients with CAD. Although reports indicate that DES are used in 75% of PCI procedures in
he U.S. (34), their use varies widely from hospital to
ospital, and in some U.S. states, DES use is actually less
han BMS use. For example, recent data indicate that only
9% of PCI cases in Arkansas used a DES, with rates
ropping down to 35% for rural hospitals (286). Irrespective
f the specific reasons for this disparity, this report confirms
he BMS are still used in contemporary practice. Ultimately,
he decision to implant a BMS is guided by both clinical and
conomic factors.
linical justification for stent selection. The overall net
linical benefit of a stent can be summarized after consid-
ring the stent’s beneficial and adverse effects. The benefits
f DES are their significant reduction in repeat revascular-
zation compared with use of a BMS, whereas their adverse
ffects relate to the increased risk of very late ST and the
equirement for prolonged DAPT (22–26). Importantly,
he net benefit cannot be assessed by simply determining the
ifference between these 2 outcomes, as they both have a
ifferent incidence and clinical consequence. For example,
lines]) between 1 year and 2 years may explain the reduction in the absolute
revascularization (TLR), and (D) ischemic major adverse cardiovascular events
ear follow-up. However, events rates remained lower with EES, and a much
uced with permission from Garg et al. (275). HR  hazard ratio.[white
lesion
) at 2-y
eprodn a study by Stone et al. (287), the rate of ST and TLR was
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espectively, whereas the rate of death and MI within 7 days
or these events was 91.1% for ST and 3.5% for TLR.
herefore, to assess the overall net clinical benefit, actual
ortality must be considered. Extensive data exist to con-
rm that DES not only significantly reduce restenosis
ompared with BMS, but do so without increasing the risk
f mortality or MI. Thus, the overall net clinical benefit
avors DES.
It must be appreciated, however, that this benefit in favor
f DES is not universal, and in certain patients and lesions
his net benefit may ultimately favor a BMS. The advantage
f a DES in terms of reducing restenosis is dependent on
esion characteristics, and the observed benefit is greater in
esions at higher risk for restenosis. For example, the
bsolute difference in rates of repeat revascularization be-
ween DES and BMS for lesions in vessels 3 and 3 mm
n diameter in the BASKET trial at 3-year follow-up was
.1% and 2.0%, respectively (288). Similarly, in the Ontario
egistry, Tu et al. (289) reported a significantly lower rate of
VR with the use of DES compared with BMS among
iabetic patients who had lesions that were20 mm long in
essels 3 mm in diameter (DES vs. BMS 7.2% vs. 17.6%,
R: 0.38, 95% CI: 0.24 to 0.60, p 0.001; number needed
o treat to prevent TVR  10). Conversely, no significant
ifferent in TVR was seen between DES and BMS when
atients were not diabetic and had lesions 20 mm long in
essels 3 mm in diameter (DES vs. BMS 5.3% vs. 5.9%,
R: 0.87, 95% CI: 0.52 to 1.47, p  0.61; number needed
o treat to prevent TVR 167) (289). The risk of ST is also
ariable and may be increased for patients who are not
illing to, or are unlikely to, comply with DAPT, or for
atients awaiting elective surgery (146,172). Therefore, for
atients whose risk of restenosis is relatively low (i.e.,
ondiabetic, large vessel 3 mm in diameter), and/or the
isk of ST is relatively high (inability to comply with
ong-term DAPT), a BMS maybe more appropriate. Ulti-
ately, an evaluation of the overall risk/benefit ratio should
lay a key role in the clinical decision whether to implant a
MS or DES.
ost effectiveness. Unfortunately, the discussion of stent
election cannot be made without considering the cost
ffectiveness of both therapies, in view of the additional
nitial expense associated with using a DES. Numerous
ost-effectiveness analyses have been performed with con-
icting results. Of note, many studies group patients treated
ith different DES together as 1 population, which ulti-
ately can affect the accuracy of cost-effectiveness calcula-
ions for individual stents.
Some studies indicate that DES may be cost effective or
ven cost saving with specific patients, such as those who
ave lesions with a high risk for restenosis such as diabetic
atients, long lesions, and lesions in vessels with small
iameters. In the BASKET study, for example, DES were oore effective and less expensive for vessels 3.0 mm
iameter. For vessels 3.0 mm diameter, although the
verall cost per quality-adjusted life-year gained was
39,641 ($59,392), subgroup analysis revealed that the cost
er quality-adjusted life-year gained was €6,863 ($10,282)
or off-label use, €3,471 ($5,200) for lesions 24 mm in
ength, and €300 ($450) for patients65 years of age (290).
onversely, other studies report an incremental cost-
ffectiveness ratio of 200,000 Canadian dollars per
uality-adjusted life year—indicating DES are not cost
ffective (291).
Importantly, the use of angiographic follow-up in ran-
omized controlled trials and a short period of follow-up are
major factors that can bias results in favor of DES.
evertheless, a recent systematic review evaluated 19 dif-
erent cost-effectiveness studies that mainly reported results
t 1 year, and concluded that the cost effectiveness of DES
as unfavorable compared with that of BMS. That was
rimarily because, although the use of DES was associated
ith a higher initial cost (€700 [$1,060]), they did not
ncrease life expectancy, produced only a small relative
eduction in rates of repeat procedures, and led to only a
hort duration of improved quality of life (291).
Further data suggesting DES are not cost effective come
rom analysis at 1 year of the outcomes from patients in
rance enrolled in the TYPHOON (Trial to Assess the Use
f the Cypher Stent in Acute Myocardial Infarction Treated
ith Balloon Angioplasty), which reported the mean ag-
regate 1-year costs were €1,142 ($1,711) higher per patient
n the SES group compared with the BMS group. The
ncremental cost-effectiveness ratio was €7,321 ($10,972)
er TVR avoided (292).
By restricting follow-up to 1 year, previous cost-
ffectiveness studies have the potential to miss accounting
or the costs incurred with very late ST, thereby introducing
ias against BMS. To investigate the impact of long-term
ollow-up, Bischof et al. (293) performed an analysis using
Markov model to speculate on the cost effectiveness of
sing DES in the U.S. Medicare setting at 1 to 3 years of
ollow-up. Their results suggested that DES were not cost
ffective compared with BMS when used in unselected
atients with CAD in the setting of Medicare (293).
In the United Kingdom, the National Institute of Clin-
cal Excellence has taken into account the differences in cost
etween DES and BMS, and the differences in the risk of
estenosis for specific lesions. Therefore, they have recom-
ended DES in cases where lesions are 15 mm in length,
n vessels3.0 mm in diameter, provided the cost difference
etween BMS and DES is £300 or less (€330 [$500]) (294).
The increasing development of DES in the developing
orld and the expiry of the patent for sirolimus are both
ikely to lead to reductions in the cost of DES, completely
ltering the cost-effectiveness evaluations that have previ-
usly been performed.
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iabetic patients are known to have an aggressive form of
therosclerosis with less favorable long-term survival after
CI compared with that of nondiabetic patients. Moreover,
iabetes mellitus is frequently identified as an independent
redictor of ISR (295,296), although the underlying mech-
nisms for this are poorly understood. Implicated factors
nclude the greater degree of the vascular inflammation and
ndothelial dysfunction seen in diabetic patients (297,298)
ogether with poor glycemic control (299) and insulin
esistance that can aggravate restenosis through the direct
rowth factor-like effect of insulin on vascular smooth
uscle and neointimal cells (300).
MS versus DES. REGISTRY DATA. The most recent reg-
stry data come from the MDACR (Massachusetts Data
nalysis Center Registry) and the SCAAR registry, which
ave reported results for 5,051 and 19,004 diabetic patients,
espectively. The MDACR, which reported the results of
ropensity-matched diabetic patients treated with either
MS or DES, demonstrated significantly lower rates of
eath, MI, and repeat revascularization with DES at 3-year
ollow-up (301). The SCAAR registry only assessed pa-
ients treated with DES and demonstrated that, overall,
atients with diabetes were at higher risk of restenosis
ompared with nondiabetic patients. Interestingly, this was
nly true for patients treated with SES and ZES; the rate of
estenosis for patients treated with PES was not influenced
y diabetic status. Ultimately, no mortality difference was
emonstrated between the different DES (302).
ANDOMIZED DATA. The evaluation of diabetic patients with
he use of DES is hampered by the distinct lack of dedicated
andomized trials. At present, only 10 randomized trials
nrolling 1,662 patients have been conducted with DES to
pecifically assess outcomes in diabetic patients: 4 Cypher SES
ersus BMS, 5 Cypher SES versus TAXUS PES, and 1
ypher SES versus ZES (49–53,102–104,303–308). There
re no dedicated randomized trials assessing the performance
f EES in diabetics, and data are derived from the diabetic
atient subgroup (n  1,185; 786 EES, 399 PES) of the
PIRIT IV trial (279) and the diabetic subgroup of the
PIRIT V study, which randomly assigned 324 patients to
ES (n  215) or PES (n  104) (309). Similarly, the only
ata comparing ZES and PES are derived from 477 diabetic
atients (241 ZES, 236 PES) in a subgroup analysis of the
NDEAVOR IV study (310).
AFETY. Pooled analyses of diabetic subgroups from ran-
omized trials comparing SES to BMS and PES to BMS
mong diabetic patients have demonstrated conflict results.
paulding et al. (23) reported significantly higher mortality
ith the use of SES compared with BMS at 4-years
ollow-up (12.2% vs. 4.4%, p  0.004); however, the
uthors acknowledge that this result may have been a play of
hance, particularly in view of the small number of actual
eaths in the diabetic subgroup (SES 23 vs. BMS 10). At ehe same length of follow-up, Kirtane et al. (311) reported
omparable mortality between PES and BMS (PES 8.4%
s. BMS 10.3%, p  0.61), and reassuringly, a collaborative
etwork analysis by Stettler et al. (312) that included 3,850
atients demonstrated no significant difference in mortality
etween SES, BMS, and PES in the treatment of diabetic
atients who received DAPT for 6 months.
Among different DES, no differences in mortality or MI
ave been noted. A recent meta-analysis (313) of 5 dedi-
ated randomized trials comparing SES to PES—the
SAR-DIABETES (Intracoronary Stenting and Angio-
raphic Results: Do Diabetic Patients Derive Similar Benefit
rom Paclitaxel-Eluting and Sirolimus-Eluting Stents?),
ES-DIABETES (Drug-Eluting Stents in Patients With
iabetes Mellitus), and DiabeDES (Diabetes and Drug
luting Stent) trials, and studies by Kim et al. (303) and
omai et al. (307)—that in total enrolled 1,069 patients,
ith follow-up of as long as 2 years, reported no significant
ifference between SES and PES with respect to mortality
OR: 0.78, 95% CI: 0.30 to 2.07) or the risk of MI (OR:
.88, 95% CI: 0.33 to 2.38). No significant differences in
ortality, MI, or ST were reported at 12-month follow-up
etween either ZES and PES, or between EES and PES in
he SPIRIT IV study. In the SPIRIT V diabetic cohort,
reatment with EES led to a significantly lower risk of the
omposite of cardiac death/MI (3.7% vs. 9.6%, p  0.04),
hich was driven by the significantly lower rate of MI with
ES (309). The rate of ST was 0.0% for EES and 1.9% for
ES.
FFICACY. Clinical data indicate the superior performance
f the SES with respect to BMS and both PES and ZES.
he 4 dedicated randomized trials comparing SES to BMS
DECODE [A Randomized Study With the Sirolimus-
luting Bx Velocity Balloon-Expandable Stent in the
reatment of Diabetics Patients With Native Coronary
rtery Lesions], SCORPIUS [German Multicenter Ran-
omized Single Blind Study of the CYPHER Sirolimus-
luting Stent in the Treatment of Diabetic Patients With
e Novo Native Coronary Artery Lesions], DESSERT [Di-
betes Drug-Eluting Sirolimus Stent Experience in Restenosis
rial], and DIABETES [Diabetes and Sirolimus-Eluting
tent]) have collectively enrolled 600 patients, and have all
emonstrated significant reductions in their primary end point
f in-segment late loss at between 6 and 9 months of
ollow-up. Furthermore, although not powered to detect dif-
erences in clinical outcomes, they have also all shown signif-
cant reductions in TLR at follow-up of between 8 and 48
onths.
Similarly, 4 of the 5 dedicated randomized trials compar-
ng SES to PES have demonstrated significant reductions in
n-segment late loss for SES compared with PES. With
espect to reintervention, no significant difference has been
hown in any of the individual trials apart from the
ES-DIABETES study, which reported a somewhat un-
xpected 75% reduction in reintervention at 2 years for SES
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5% CI: 0.08 to 0.77, p  0.004). Meta-analysis of these 5
rials, which include a total of 1,069 patients with follow-up
f as long as 2 years, has indicated that overall treatment
ith SES is associated with significant reductions in reste-
osis (OR: 0.29, 95% CI: 0.18 to 0.47) and reintervention
OR: 0.47, 95% CI: 0.28 to 0.77), compared with PES (313).
The DiabeDES III study is the only randomized com-
arison involving treatment with ZES. This study randomly
llocated 127 diabetic patients to either ZES or SES, and
emonstrated significantly lower late lumen loss with SES
0.14 mm vs. 0.74 mm, p  0.001) at 10-month follow-up
308). In the subgroup of diabetic patients returning for
ngiographic follow-up in the ENDEAVOR IV study (n
6), a trend toward higher in-stent late loss was seen in
atients treated with ZES compared with SES (0.81 vs.
.56, p  0.073), whereas no notable differences in 1-year
LR were seen (310). Similarly, in the SPIRIT IV study,
espite significant reductions at 1 year in TLR, TVR,
ACE, and target vessel failure among nondiabetic pa-
ients treated with EES compared with PES, no significant
ifferences in any of these outcomes were seen among
iabetic patients (279). In the SPIRIT V study, EES was
hown to be noninferior and subsequently superior to PES
ith respect to in-stent late loss at 9 months (0.19 mm vs.
.39 mm, pnoninferority 0.0001, psuperiority  0.0001); rates
f repeat revascularization remained comparable between
oth stents (309). Some of these results are at variance with
he meta-analysis by Kastrati et al. (313), and therefore,
eiterate that there is presently no clear evidence to indicate
hat “limus”-based DES are superior to paclitaxel in the
reatment of coronary lesions in diabetic patients.
ES versus CABG for diabetic patients. The CARDia
Coronary Artery Revascularization in Diabetes Trial) is the
nly randomized trial comparing the management of dia-
etes with multivessel disease (MVD) between CABG and
CI; however, because of poor recruitment, it was discon-
inued early after enrolling only 510 of the desired 600
atients, and is therefore largely underpowered. The ulti-
ately negative noninferiority trial found no significant
ifference in 1-year mortality (3.2% PCI vs. 3.3% CABG,
 0.83) or the 1-year composite clinical end point of
eath, nonfatal MI, or nonfatal stroke (10.2% for PCI vs.
1.8% for CABG); however, repeat revascularization was
equired more frequently in the PCI group (9.9% vs. 2.0%,
 0.001). Although PCI was performed with DES in
nly 71% of cases, even these patients had higher rates of
epeat revascularization when compared with CABG (7.3%
s. 2.0%, p  0.013) (314).
More recently, the SYNTAX (Synergy Between Percu-
aneous Coronary Intervention With Taxus and Cardiac
urgery) study, although not a dedicated randomized trial of
iabetic patients, did enroll 452 diabetic patients (221
ABG, 231 PCI). Results demonstrated a higher rate of
ajor adverse cardiovascular and cerebrovascular events
MACCE) for patients treated with PCI that was mainly Driven by significant higher rates of repeat revascularization.
verall, the presence of diabetes increased mortality for
oth revascularization strategies (315). Further information
bout the optimal treatment for diabetic patients with
VD will be known with the results of the ongoing
REEDOM (Future Revascularization Evaluation in Pa-
ients With Diabetes Mellitus: Optimal Management of
ultivessel Disease) trial (316).
TEMI
nvasive reperfusion therapy has improved the prognosis of
atients with STEMI (317,318), and new recommendations
rom the American College of Cardiology/American Heart
ssociation (ACC/AHA) indicate that DES are a reasonable
lternative to BMS for these patients (319). There have been
oncerns, however, that the use of DES in this setting may
redispose to a higher risk of ST (143,320,321), which may
esult from the following: 1) the trapping of thrombus behind
tent struts and subsequent thrombus resolution, which can
ead to an increased risk of ISA; 2) the protrusion of stent struts
nto underlying necrotic core due to overlying plaque rupture;
) a delay in arterial healing (e.g., greater incomplete stent strut
ndothelialization and persistent fibrin deposition) that has
een recognized at the culprit site in patients with STEMI
ompared with patients treated for stable angina (322); and 4)
igh risk of adverse events for patients noncompliant to
APT, as suggested by results from the PREMIER (Prospec-
ive Registry Evaluating Myocardial Infarction: Events and
ecovery) study, which reported a significantly increased 11-
onth mortality among the 13.6% of patients who discontin-
ed DAPT 30 days after their revascularization for ACS or
TEMI (172).
Clinical data on outcomes from primary PCI are limited
t present by the short duration of follow-up in most
tudies. The largest randomized primary PCI trial to date,
he HORIZONS-AMI (Harmonizing Outcomes With
evascularization and Stents in Acute Myocardial Infarc-
ion) study, has reported angiographic data and clinical
utcomes at 13 and 24 months, respectively, among 3,006
TEMI patients treated with PES or BMS. At 13 months,
here were significant reductions in in-stent late loss and
inary restenosis with PES (91). At 24 months of clinical
ollow-up, the use of PES was associated with significant
eductions in the respective primary and second efficacy end
oint of ischemia-driven TLR (p  0.001) and ischemic
VR (p  0.001). In addition, there were no significant
ifferences at 24 months between PES and BMS in the
rimary safety end point, a composite of death, MI, stroke
r ST (PES 11.0% vs. BMS 11.2%, p  0.90), or all-cause
ortality, cardiac death, reinfarction, or definite/proba-
le ST (92).
A previous meta-analysis by Kastrati et al. (323) of 2,786
atients undergoing primary PCI reported no significant
ifference in terms of death, MI, or ST between BMS or
ES, and significant reductions in the risk of reintervention
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Coronary Stents: Current Status August 31, 2010:S1–42ith DES (HR: 0.38, 95% CI: 0.29 to 0.50, p  0.001).
nfortunately, follow-up was limited to 2 years (323).
More recently, Brar et al. (324) performed a much larger
eta-analysis of 13 randomized trials that included 7,352
atients followed up for a maximum of 2 years. Results
gain demonstrate no significant difference between BMS
nd DES in terms of mortality (RR: 0.89, 95% CI: 0.70 to
.14), MI (RR: 0.82, 95% CI: 0.64 to 1.05), and ST (RR:
.97, 95% CI: 0.73 to 1.28), whereas the use of DES led to
significant reduction in repeat TVR (RR: 0.44, 95% CI:
.35 to 0.55, p  0.001). Notably, this benefit in reduced
VR was consistent in patients irrespective of whether
APT was given for6 months or6 months, or whether
ollow-up was for 1 year or 1 year. Another important
bservation was that the benefit seen with DES treatment
as greater for patients at highest risk of restenosis (324). A
oncurrent meta-analysis of 18 registries that included
26,000 patients was performed by the same group, and
as shown similar results, with comparative outcomes in
erms of death and MI between DES and BMS and
ignificant reductions in terms of repeat revascularization
ith DES at up to 3-year follow-up (324).
Long-term follow-up data (4 years) that are available
rom 1 registry and 4 randomized studies have shown
onflicting results. The randomized TYPHOON study, the
ASEO (Paclitaxel or Sirolimus-Eluting Stent Versus Bare
etal Stent in Primary Angioplasty) study, and the
TRATEGY (Single High-Dose Bolus Tirofiban and
irolimus-Eluting Stent Versus Abciximab and Bare Metal
tent in Myocardial Infarction) study, which all randomly
Figure 14 Rates of Stent Thrombosis Comparing DES to BMS
Rates of early/late and very late definite stent thrombosis (ST) in randomized trial
bars) to bare-metal stents (blue bars) among patients undergoing primary percuta
cant, the rates of early/late ST are numerically higher with bare-metal stents, whe
Academic Research Consortium.ssigned STEMI patients to treatment with either DES and (MS, have all shown positive results in favor of using DES
ith respect to reduced rates of repeat revascularization, and
omparable safety at between 4- and 5-year follow-up
58,62,64). Specifically, the TYPHOON study, which ran-
omly allocated 715 STEMI patients to treatment with
ither BMS or SES, demonstrated no significant differences
n rates of death, cardiac death, and MI at 4-year follow-up,
hereas rates of TLR and TVR were significantly lower in
he SES group. With respect to ST, although the overall
ate was comparable between groups (SES 3.6% vs. BMS
.0%, p  0.82), very late ST was numerically higher with
ES (2.0% vs. 0.8%) (Fig. 14) (64). These results need to be
nterpreted with caution, considering the extensive exclu-
ion criteria used during enrollment (only 35% of screened
atients were enrolled) (63) and that complete follow-up
as available for only 70% of patients.
At variance with these results are data from a large
ingle-center registry of 1,738 patients by Kukreja et al.
325) and the 5-year follow-up results of the 619-patient
ASSION (Paclitaxel-Eluting Stent Versus Conventional
tent in Myocardial Infarction With ST-Segment Eleva-
ion) randomized trial (95). Kukreja et al. (325) reported no
verall significant differences between DES (SES, n  185;
ES, n  1,022) and BMS (n  531) in all-cause mortality
BMS 16.4% vs. SES 11.4% vs. PES 12.9%) or repeat
evascularization (8.0% vs. 7.0% vs. 6.9%, respectively) at a
edian follow-up of 1,185 days. Moreover, although there
ere no differences in overall, early, or late ST rates, there
ere no cases of very late ST in the BMS group compared
ith a rate of 2.7% and 0.9%, respectively, in the SES group
paring paclitaxel-eluting stents (green bars) and sirolimus-eluting stents (red
coronary intervention at long-term follow-up. Although no differences are signifi-
e rates of very late ST are numerically greater with drug-eluting stents. ARC s com
neous
reas thp  0.001) and the PES group (p  0.03).
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August 31, 2010:S1–42 Coronary Stents: Current StatusSimilarly, in the PASSION study, which had consi-
erably fewer exclusion criteria compared with the
YPHOON study and enrolled 60% of patients who were
creened, no significant differences were observed in overall
ACE, mortality, reinfarction, and TLR between patients
reated with PES or BMS out to 5-year follow-up. Overall
ates of definite/probable ST were comparable (PES 3.9%
s. BMS 3.4%, p 0.85); however, rates of late/very late ST
ere approximately 3 times higher among patients treated
ith PES (3.2% vs. BMS 1.1%, p  0.09) (Fig. 14). Again,
hese results must interpreted with caution considering the
elatively small sample size and the lack of power to detect
ifferences in ST.
ultivessel CAD
he debate over the optimal method of revascularizing
atients with MVD has raged for many years and continues
o this day. The importance of this patient subgroup cannot
e under estimated considering the increasing age and
ultiple comorbidities of patients currently being investi-
ated for CAD, and the correspondingly higher number of
atients with MVD ultimately requiring revascularization
326). Historically, CABG has been the accepted treatment
or MVD (327); however, advances in the percutaneous
reatment of CAD have made PCI a more attractive
lternative (28,77,328). Despite this, observational data
rom real-world practice indicate that for two-thirds of
atients with complex CAD, cardiac surgery remains the
referred method of revascularization, findings that have
een supported by a recent prospective randomized trial
28,329).
MS versus CABG. A meta-analysis of the 4 randomized
rials comparing outcomes at 5-year follow-up in patients
ith MVD treated with either a BMS or CABG showed a
imilar rate of the composite of death, stroke, and MI (PCI
6.7% vs. CABG 16.9%; HR: 1.04, 95% CI: 0.86 to 1.27,
 0.69); a numerically higher rate of stroke with CABG
PCI 3.1% vs. CABG 3.9%; HR: 1.16, 95% CI: 0.73 to
.83, p  0.54); and a significantly higher rate of repeat
evascularization with the use of a BMS (29.0% vs. 7.9%;
R: 0.23, 95% CI: 0.18 to 0.29; p  0.001) (330). A much
arger meta-analysis by Bravata et al. (331) that included 23
andomized controlled trials comparing PCI (POBA or
MS; n  5,019) with CABG (n  4,944) showed that
espite a significantly higher rate of procedure-related
troke after CABG (1.2% vs. 0.6%, p  0.002), and more
requent repeat revascularization after PCI (absolute risk
ifference 24% at 1 year and 33% at 5 years), there was no
ifference in survival between percutaneous and surgical
ntervention. More recently, Hlatky et al. (332) performed a
ollaborative analysis using patient data from trials compar-
ng POBA and BMS to CABG and reported somewhat
imilar findings, with significantly higher stroke rates at 90
ays after CABG, significantly higher repeat revasculariza-
ion after PCI, and no overall significant difference in terms 1f mortality at a median of 5.9 years of follow-up (PCI 15%
s. CABG 16%, HR: 0.91, 95% CI: 0.82 to1.02, p  0.12).
MS versus DES. The development of DES led to
ignificant reductions in the rates of restenosis and repeat
evascularization when compared with BMS. Consequently,
f PCI is selected, there is little debate over whether to use
DES or a BMS; in fact, some would argue that patients
ith MVD where a DES cannot be used should be offered
urgical revascularization. Currently, no dedicated prospec-
ive randomized trials have been performed comparing DES
nd BMS for patients specifically with MVD, and data
upporting the use of DES in these patients, as opposed to
MS, come from the extrapolation of data from registries,
ondedicated trials, and subgroup analyses. The ARTS-II
tudy recruited 607 patients with 2- or 3-vessel disease
reated with DES, who were then compared with patients
ith 2- or 3-vessel disease treated with BMS who were
ecruited in the ARTS-I study. At 5-year follow-up, there
as no significant difference in survival (DES 94.5% vs.
MS 92.0%), whereas the use of DES led to significant
eductions in repeat revascularizations (20.8% vs. 30.9%,
 0.001) and overall MACCE (27.5% vs. 41.5%, p 
.001) (Fig. 4) (77).
At variance with these results is the risk-adjusted out-
omes among 60,000 patients undergoing PCI or CABG in
he New York cardiac registry (333). Results suggested a
ignificantly higher risk-adjusted survival among the CABG
roup (HR: 0.64, 95% CI: 0.56 to 0.74), with the difference
eing most pronounced in patients with 3-vessel disease and
roximal left anterior descending artery disease. Complete
isk adjustment was impossible to achieve, particularly as
linical judgment could not be adjusted for in this complex
ohort of patients.
ES versus CABG. Data comparing the outcomes in
atients with MVD treated with DES and CABG were
nitially derived from the addition of DES arms to the initial
MS-CABG trials, to allow a comparison of outcomes
etween DES and historical CABG cohorts. This was
erformed in the ARTS-II study, which at 5 years again
emonstrated no significant difference in survival between
ES and CABG (DES 94.5% vs. CABG 92.6%), but
ignificantly higher rates of repeat revascularization (20.8%
s. 9.0%, p  0.001) and MACCE (27.5% vs. 21.1%, p 
.02) with the use of DES (Fig. 4) (77). A similar approach
as performed in the ERACI-III (Argentine Randomized
tudy: Coronary Angioplasty With Stenting Versus Coro-
ary Bypass Surgery in Multi-vessel Disease) study, which
dded 225 DES patients to the 500 patients (225 BMS, 225
ABG) in the ERACI-II study. At 1-year follow-up,
reedom from adverse events was significantly greater
mong patients treated with DES (88.0% vs. 80.5% CABG,
 0.038), whereas at 3-year follow-up, event rates were equal
77.3%, p  1.0). This convergence was largely driven by the
ignificantly higher TVR in the PCI cohort at 3 years (5.8% vs.
4.2%, p  0.002). Of note, mortality was highest in the
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Coronary Stents: Current Status August 31, 2010:S1–42ohort treated with CABG at both 1-year follow-up (3.1% vs.
.6%, RR: 0.41, 95% CI: 0.17 to 0.97) and 3-year follow-up
5.7% vs. 9.8%, RR: 0.59, 95% CI: 0.31 to 1.14) (334).
Observation data, again from the New York cardiac
egistry, of 17,400 patients reported similar rates of unad-
usted survival at 18 months between DES and CABG in
atients with 3-vessel (93.7% vs. 93.4%, p not significant)
nd 2-vessel (95.0% vs. 94.9%, p  not significant) disease.
owever, after adjustment of variables that are difficult to
djust for, such as the judgment of the treating physician,
utcomes in favor of CABG were obtained (94.0% vs.
2.7%, p 0.03; and 96.0% vs. 94.6%, p 0.003 for 3- and
-vessel disease, respectively) (335,336).
The only randomized data comparing DES to CABG in
atients with MVD comes from the previously discussed
ARDia trial, and the SYNTAX (Synergy Between Per-
utaneous Coronary Intervention With Taxus and Cardiac
urgery) study (28,314). The SYNTAX study was a large,
rospective, multicenter, “all-comers” trial that assessed
utcomes in 1,800 patients with either left main (705
atients: PCI 357, CABG 348) or 3-vessel disease (1,095
atients: PCI 546, CABG 549) randomly allocated to
reatment with either PCI (with PES) or CABG (28). The
ll-comers study design and the use of the SYNTAX score
llowed the study to address the important limitations of
reviously conducted randomized trials comparing PCI and
ABG. These limitations included patient selection; for
xample, in studies comparing BMS to CABG, only 4% of
hose initially screened were eventually randomized (330),
ith a common exclusion being patients with impaired left
entricular function (327). Second, all patients with MVD
re not the same, and the previous trials did not include any
ethods of categorizing the extent of MVD or the lesion
omplexity to allow results to be put into context and
tratified according to disease severity.
Among patients with triple-vessel disease, the overall
espective rates of death (4.1% vs. 6.5%; p  0.07), cardiac
eath (2.3% vs. 4.5%; p  0.05), stroke (2.3% vs. 1.7%; p 
.47), MI (2.8% vs. 6.1%; p  0.009), repeat revascular-
zation (7.5% vs. 17.4%; p  0.001), and MACCE
14.4% vs. 23.8%; p  0.001) favored CABG at 2-year
ollow-up. Moreover, as shown in Figure 15, when
utcomes are stratified according to disease complexity
sing the SYNTAX score, outcomes between PCI and
ABG are only comparable among patients in the lowest
YNTAX score tercile (22) (337).
PLMS Disease
sing PCI for UPLMS disease was deemed inappropriate
ccording to the 2009 ACC/AHA appropriateness criteria
or coronary revascularization, which was in line with
uidelines from the U.S. and Europe that both gave PCI for
PLMS a Class III indication for patients suitable for
ABG (338,339). However, despite these guidelines, in
006, approximately one-quarter of UPLMS disease was
till treated by PCI (329). More recently, a white paper that cncludes a comprehensive review of the literature was
ublished in this Journal, and suggests that in specific
atients and lesions, PCI may offer a suitable alternative to
ABG (340). Following on from this, the 2009 focused
pdate on PCI published by the ACC/AHA has upgraded
CI for UPLMS to a Class IIb indication, and it may be
onsidered for appropriate patients, namely, those with
oronary anatomy that is associated with a low risk of
rocedural complication if treated by PCI and/or clinical
onditions that predict an increased risk of adverse surgical
utcomes (319). Unfortunately, current studies assessing
utcomes in UPLMS stenting are limited by being largely
bservational with relatively short follow-up.
MS versus DES. In brief, at present there is only 1
andomized trial comparing outcomes between DES and
MS for PCI of UPLMS (96). Erglis et al. (96) enrolled
03 patients randomly assigned to PCI with either PES or
MS and reported, as expected, that at 6-month follow-up,
he use of DES leads to significant reductions in repeat
evascularization when compared with BMS without expos-
ng patients to any additional risk of death, MI, or ST.
urther comparisons between BMS and DES in UPLMS
CI, from largely nonrandomized, observational studies
ith follow-up ranging from 6 months to 3 years, report
imilar findings. These results, however, must be taken in
he context of the observational nature of the studies
nvolved and the subsequent limitations that encompasses,
uch as patient selection and a lack of statistical power to
emonstrate differences in events and ST (340).
ES versus PES. Three studies have assessed the out-
Figure 15 MACCE Among Patients With
Triple-Vessel Disease in the SYNTAX Trial
The rates of major adverse cardiovascular and cerebrovascular events (MACCE
[a composite of death, stroke, myocardial infarction, and repeat revasculariza-
tion]) at 2-year follow-up among patients with triple-vessel disease treated with
percutaneous coronary intervention (PCI [blue bars]) or coronary artery bypass
graft surgery (CABG [red bars]) in the SYNTAX trial. For patients with a SYNTAX
score between 0 and 22, PCI offers a suitable alternative to CABG (339).omes of UPLMS PCI between patients treated with SES
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AIN (Intracoronary Stenting and Angiographic Results:
rug-Eluting Stents for Unprotected Coronary Left Main
esions) study represents the only dedicated randomized
tudy, and at 1 year, there was no significant difference in
he primary end point, a composite of death, MI, or TLR,
etween SES or PES (PES 13.6% vs. SES 15.8%, p 0.44)
113). In addition, angiographic restenosis at 6- to 9-month
ollow-up (PES 16.0% vs. SES 19.4%, p  0.30), mortality
PES 10.7% vs. SES 8.7%, p 0.64), and UPLMS-specific
LR (PES 9.2% vs. SES 10.7%, p  0.47) at 2-year
ollow-up, together with ST were all comparable between
ES and PES. Longer follow-up is available from subgroup
nalyses of the DELFT (Drug-Eluting Stent for Left
ain) registry and MAIN-COMPARE (Revascularization
or Unprotected Left Main Coronary Artery Stenosis:
omparison of Percutaneous Coronary Angioplasty Versus
urgical Revascularization) registry. At 3-year follow-up,
oth studies demonstrated similar adjusted rates of death,
I, and TVR, and comparable ST (341,342).
CI versus CABG. Consistent with the previous discus-
ion on MVD, PCI in patients with UPLMS has shown
imilar safety outcomes, and consistently higher rates of
epeat revascularization compared with CABG. The non-
andomized MAIN-COMPARE registry that enrolled
,240 patients (1,138 CABG and 1,102 who had PCI: 318
MS, 784 DES) is the largest single study comparing PCI
o CABG to date. At 3-year follow-up, outcomes among a
Figure 16 MACCE Among Patients With Left Main Disease in t
The rates of safety (death, stroke, and myocardial infarction [MI]) and efficacy (ma
stroke, MI, and repeat revascularization) among patients with left main disease tre
bypass graft surgery (CABG [red bars]) in the SYNTAX trial. For SYNTAX scores be
and above, CABG is superior (347).ropensity-matched cohort of patients were comparable in serms of death (HR: 1.18 for PCI, 95% CI: 0.77 to 1.80,
 0.45) and MACCE (HR: 1.10 for PCI, 95% CI: 0.75
o 1.62, p  0.61), whereas repeat revascularization was
ignificantly higher in the PCI group (HR: 4.76, 95% CI:
.80 to 8.11, p 0.001), with DES performing much better
han BMS (26). At 5-year follow-up, overall results were
nchanged (343). Of note, similar findings have also been
eported out to 3-year follow-up in a meta-analysis of 3,773
atients with UPLMS undergoing revascularization by PCI
r CABG (344).
The UPLMS subgroup from the SYNTAX trial (357
CI, 348 CABG) represents the largest cohort of patients
andomized to either PCI or CABG. In the overall UP-
MS group at 2 years, 22.9% and 19.3% of patients treated
ith PCI and CABG, respectively, reached the primary end
oint of MACCE (p  0.27), a composite of mortality
PCI 5.6% vs. CABG 6.2%, p  0.77), MI (5.5% vs. 4.1%,
 0.45), stroke (0.9% vs. 3.7%, p  0.01), and repeat
evascularization (17.3% vs. 10.4%, p  0.01).
The stratification of outcomes according to the SYN-
AX score has demonstrated that for patients with scores
etween 0 and 32, PCI with PES may be safer and as
fficacious as CABG, whereas for patients with scores 33,
ABG offers a safer and more efficacious treatment, albeit
t a higher risk of stroke (Fig. 16). In the overall SYNTAX
tudy population, 421 of the 1,212 patients with UPLMS
isease had a SYNTAX score between 0 and 32, indicating
hat approximately one-third of patients with UPLMS are
NTAX Trial
erse cardiovascular and cerebrovascular events [MACCE], a composite of death,
ith percutaneous coronary intervention (PCI [blue bars]) or coronary artery
0 and 32, PCI appears to be as safe and efficacious as CABG; for scores of 33he SY
jor adv
ated w
tweenuitable for PCI (345).
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Coronary Stents: Current Status August 31, 2010:S1–42The results from the SYNTAX trial have fuelled the
ebate with respect to the management of UPLMS disease,
nd prompted the first dedicated UPLMS trial, the
XCEL (Evaluation of Xience Prime Versus Coronary
rtery Bypass Surgery for Effectiveness of Left Main
evascularization) study, which will randomize 2,500 pa-
ients to revascularization with either the Xience V PRIME
ES or CABG. The trial aims to commence enrollment in
ate 2010 (346).
TO
TOs are encountered in15% to 30% of patients referred
or coronary angiography, and generally regarded as 1 of the
ew remaining challenges for interventional cardiologists
347). They are associated with lower procedural success
ates compared with nonocclusive lesions, with inability to
ross the CTO with a wire as the most commonly cited
eason for procedural failure (347).
Successful percutaneous recanalization of a CTO, com-
ared with a failed attempt, offers the benefit of a reduction
n symptoms, improved left ventricular function, and im-
roved survival (348–351). For example, the 376-patient
ulticenter TOAST-GISE (Total Occlusion Angioplasty
tudy–Società Italiana di Cardiologia Invasiva) study re-
orted significant reductions in mortality (1.05% vs. 7.23%,
 0.005), and a greater rate of angina-free survival (88.7%
s. 75.0%, p  0.008) among patients with successful
TO-PCI compared with patients who had an unsuccessful
TO-PCI attempt at 12-month follow-up (348). The
ong-term prognostic benefits of successful versus unsuc-
essful CTO intervention at both 5- and 10-year follow-up
ave also been demonstrated by Hoye et al. (351) (93.5 vs.
8.0%, p  0.02) and Suero et al. (350) (73.5% vs. 65.1%,
 0.001), respectively. In contrast, however, Prasad et al.
352), who reviewed outcomes over 25 years in a single center,
eported that an unsuccessful procedure was not an indepen-
ent predictor of long-term mortality; whereas de Labriolle et
l. (353) also reported that patients with a successful CTO
rocedure had no survival benefit compared with patients
aving an unsuccessful procedure.
ES versus BMS. After successful recanalization of a
TO, studies demonstrate consistent improvements in
linical outcomes after implantation of a DES compared
ith a BMS that have been predominantly driven through
eductions in repeat revascularization (66–69,354–360).
Randomized data are limited to the PRISON II (Primary
tenting of Totally Occluded Native Coronary Arteries II)
tudy and the GISSOC II-GISE (Gruppo Italiano di
tudio sullo Stent nelle Occlusioni Coronariche II–Società
taliana di Cardiologia Invasiva) study, which both com-
ared outcomes of patients with a CTO treated with BMS
r SES. The use of SES compared with BMS led to
ignificant reductions in TLR and TVR, and comparable
ates of death, MI, and ST at follow-up ranging from 6
onths (PRISON II), to 24 months (GISSOC II-GISE),
nd out to 5 years (PRISON II) (Table 2) (66–69). oNumerous registries have also reported data from CTO
ubgroups, and results demonstrate a consistent significant
eduction in TLR and MACE after use of DES compared
ith BMS at short-term follow-up of between 6 and 18
onths (357–360). At longer-term follow-up, and consis-
ent with the randomized studies, De Felice et al. (360)
eported the maintenance of this advantage with DES out
o 3 years among 283 patients treated with SES/PES (n 
24) or BMS (n  159). Conversely, no significant differ-
nces in TLR or MACE were observed among 140 patients
SES 76, BMS 64) in the CTO subgroup of the RE-
EARCH registry at either 3- or 5-year follow-up
361,362).
A recent meta-analysis of all these studies, which in-
luded 4,000 patients with a CTO treated with either a
ES (n  2,390) or BMS (n  2,004), confirms the
uperiority of DES in terms of significantly improved
fficacy and comparable safety compared with BMS at a
ean of 22 months of follow-up (363). It is noteworthy that
strong trend toward a higher rate of ST was observed in
he DES-treated cohort (RR: 2.79, 95% CI: 0.98 to 7.97,
 0.06).
VG
VGs have a limited durability; however, they are still
requently used as conduits in CABG. Their subsequent
ailure due to atherosclerosis is the most common cause of
ecurrent ischemia in surgically revascularized patients. Un-
ortunately, the optimal method of repeat revascularization
n these patients is not clearly established. Repeat surgical
evascularization exposes patients to an increased risk of
orbidity and mortality compared with their primary op-
ration, without evidence of prognostic gain (364,365).
oreover, PCI for SVG is associated with suboptimal
esults due to high rates of periprocedural MI and high rates
f restenosis requiring TLR (366). The high rates of peri-
roceduralMI are thought to relate to the poor development of
brous caps in the SVG atheroma (367) that increases the
ikelihood of embolization during stent implantation. The
ncidence of these periprocedural MIs is reduced after the use
f embolic protection devices (368–370); however, despite
his, and their class I recommendation for use when tech-
ically feasible (174), analysis of the ACC National Car-
iovascular Data Registry suggests that they are used in only
22% of SVG PCI (371).
Unlike native vessel lesions, the clear clinical benefits of
ES over BMS have been slow to materialize in patients
ith SVG. Currently there is a paucity of data investigating
he benefits of BMS over DES, and what data are available,
re largely retrospective (372).
andomized data. There have been only 2 small dedi-
ated, randomized studies comparing DES to BMS in SVG
ntervention, which in total have included 155 patients
74,75,373). At short-term follow-up of 6 and 18 months,
espectively, both the single-center RRISC (Reduction
f Restenosis in Saphenous Vein Grafts With Cypher
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August 31, 2010:S1–42 Coronary Stents: Current Statusirolimus-Eluting Stent) trial, and the multicenter SOS
Stent or Surgery) study reported, as expected, significant
eductions in binary restenosis and TLR after use of DES
ompared with BMS, together with comparable rates of
eath and MI (74,373). Long-term data to a median of 32
onths are only available in the RRISC trial, and demon-
trates catch-up in the repeat revascularization rates in
atients treated with DES (75). Moreover, there was a
ignificant increase in late mortality among patients treated
ith SES as compared with patients treated with BMS
29% vs. 0%, p 0.001) (75). Because of their small sample
izes, both studies were very underpowered to detect true
ifferences in clinical events.
egistry data. Twenty registries have reported results in
atients with SVG PCI, including a total of 5,172 patients
3,091 DES, 2,081 BMS), with outcomes reported between
and 34 months of follow-up. Results have been inconsis-
ent, with some reporting advantages for DES over BMS,
131,374–378), and some reporting no difference (379–382).
he largest study to date, a subgroup of the large multi-
enter STENT study, has recently reported 2-year propen-
ity score matched outcomes for 1,000 patients treated with
ES or BMS. At 9-month follow-up, the use of DES was
ssociated with significantly reduced rates of MACE (14%
s. 21%, p  0.001), a lower composite of death or MI
8.7% vs. 14%, p  0.006), and a lower rate of TVR (HR:
.36, p 0.001) and ST (HR: 0.22, p 0.009). At 2 years,
ES-treated patients had significantly better survival,
hereas significant reductions in overall MACE and TVR
ere only noted after adjustment (383).
All trials are summarized in a recently published system-
tic review (372), which concluded that in comparison to
MS, DES are safe (with the exception of the RRISC trial),
nd offer consistently reduced late loss and angiographic
tenosis. Definitive data are still needed and will be partly
btained from the results of 3 on-going randomized mul-
icenter prospective trials. In the absence of these data,
owever, for the time being, current results suggest that
ES offer an advantage over BMS in terms of reduced
estenosis and the need for TLR.
SR
he introduction of DES led to a significant reduction in
he rates of restenosis; however, they have not been able to
liminate it, resulting in a minority of patients returning
ith symptoms ranging from the gradual recurrence of
ngina pectoris to acute presentations with ACS (384,385).
umerous factors have been suggested as the underlying
echanism of this ISR, and these include: 1) biological
actors such as resistance to antiproliferative drugs and
ypersensitivity reactions; 2) mechanical factors such as
tent fractures, polymer peeling, and nonuniform stent strut
istribution or drug deposition; and 3) technical factors,
ncluding incomplete stent expansion, geographical miss,
nd barotraumas to unstented segments. aMS ISR. Historically, numerous therapies have been
sed in the management of ISR after BMS implantation
ncluding POBA, atherectomy, and repeat stenting. Al-
hough all these modalities produced satisfactory imme-
iate results, their utilization was hindered by a frequent
eed for a subsequent repeat revascularization procedure.
o address this problem, vascular brachytherapy was
ntroduced as an adjunctive therapy after successful
OBA, with subsequent randomized studies confirming
hat this combination was highly effective at reducing the
igh rates of repeat TVR after treatment of BMS ISR
386,387). The use of brachytherapy soon fell out of
avor, however, not only because of procedural logistics
uch as the expensive equipment, but also because of
esults at long-term follow-up, which raised concerns
ver ST and demonstrated a reduction in efficacy over
ime with subsequent delayed restenosis and a late TVR
atch-up response (388). Perhaps the most important
actor, however, in the downfall of brachytherapy was the
mergence of DES.
Several studies have compared the performance of
ES with brachytherapy in patients with BMS ISR. All
tudies, ranging from nonrandomized pilot studies to the
arge randomized SISR (Sirolimus-Eluting Stents Versus
ascular Brachytherapy for In-Stent Restenosis) study
nd the TAXUS V ISR study (PES vs. brachytherapy),
hich individually enrolled 400 patients, have shown a
onsistent benefit with treatment using DES (SES or
ES) compared with brachytherapy (389–395). Of note,
t long-term follow-up in the TAXUS V ISR study, a
reater absolute difference in TLR was seen at 2-year
ollow-up in favor of PES (9-month TLR 7.6% vs.
4-month TLR 11.5%), without any compromise on
afety (392). Similarly, in the SISR study, the significant
eduction in TLR with the use of SES that was observed at
2 months was maintained out to 3-year follow-up (394).
Concurrent with the comparison between DES and
rachytherapy, DES have also been compared with
OBA in the treatment of ISR after BMS implantation.
he first of such studies was the ISAR-DESIRE (Intra-
oronary Stenting and Angiographic Results: Drug-
luting Stents for In-Stent Restenosis) study that ran-
omly assigned 300 patients with BMS ISR to treatment
ith SES, PES, and POBA (116). At 6-month follow-
p, treatment with DES had led to significantly lower
ates of in-segment angiographic stenosis (POBA 44.6%
s. SES 14.3% vs. PES 21.7%, p  0.05 for SES and PES
s. POBA), whereas at 12 months, use of DES led to
ignificantly lower rates of TVR (POBA 33% vs. SES 8%
s. PES 19%, p  0.05 for SES and PES vs. POBA).
verall, rates of mortality and MI were comparable
hrough to 12-month follow-up. A secondary analysis
ompared outcomes between stents, and demonstrated no
ignificant difference between SES and PES in the rate of
ngiographic restenosis (p  0.19), whereas use of SES
l
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ES (p  0.02).
This advantage of DES over POBA appears to be
reserved long-term, as indicated by the results of the
IBS-II (Restenosis Intra-stent: Balloon Angioplasty Ver-
us Elective Sirolimus-Eluting Stenting) study that ran-
omly allocated 150 patients with BMS ISR to treatment
ith SES or POBA. At 1-year follow-up (12% vs. 31%, p
.005) and 4-year follow-up (24% vs. 35%, p  0.02),
reatment with SES had led to a significantly lower rate of
ACE, with comparable rates of death, MI, and ST. Of
ote, SES implantation was shown to be an independent
redictor of event-free survival (396,397).
ES ISR. ISR with DES is likely to become an increasing
roblem, considering the expanding use of DES in contem-
orary practice. At present, it is estimated that there are
200,000 cases of DES ISR annually in the U.S. alone (398).
espite this, however, the optimal treatment strategy for this
ondition remains to be established. The lessons learned from
he treatment of BMS ISR suggest that the most appropriate
reatment lies with repeat stenting, rather than with brachy-
herapy and POBA, and this is further supported by the more
ocal nature of DES ISR, which is a somewhat easier mor-
hological pattern to treat compared with BMS restenosis
399). Other treatment options besides stenting include surgi-
al revascularization for extreme cases and the use of more
ovel therapies such as drug-eluting balloons, which are
iscussed in more detail in Part 2 of this supplement.
If stenting is selected, a question that remains under discus-
ion is whether DES ISR should be treated with a DES
luting the same antiproliferative drug or a different class of
rug. That has recently been investigated in the ISAR-
ESIRE II study, which randomly allocated 450 patients with
SR after SES implantation to treatment with repeat SES
mplantation or PES (117). At 6-month angiographic follow-
p, there were no significant differences in late loss (SES 0.40
m vs. PES 0.38 mm, p  0.85) or binary restenosis (19.6%
s. 20.6%, p 0.69). Similarly, at 12-month clinical follow-up,
ates of death, MI, TLR, and ST were also all comparable
etween treatment strategies. Therefore, patients with SES
SR can be equally effectively treated with repeat SES implan-
ation or PES; however, it is not known whether these results
re applicable to ISR occurring after implantation of a second-
eneration DES. Importantly, the late loss observed after SES
mplantation was considerably higher than that seen in other
tudies of SES (Tables 2 and 5), suggesting that patients
xperiencing SES ISR may be hyporesponsive to the antipro-
iferative effects of SES. It follows that further investigation is
equired into the problem of ISR after DES implantation to
stablish a definitive treatment strategy.
onclusions
oronary stents are an essential component of contempo-
ary percutaneous revascularization. The introduction of
ES led to significant reductions in restenosis, and al-hough their use is associated with an increased risk of late
T, no additional risk of mortality has been demonstrated.
he improved outcomes with DES have led to expanding
ndications for PCI, which is now an accepted treatment for
iabetic patients and patients with complex CAD. The
ersisting concerns over ST have led to improvements in
tent design, and although the second-generation DES have
emonstrated early improvements in safety, great anticipa-
ion remains over the newer stent technology, which is
xplored in Part 2: Looking Forward.
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